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ABSTRACT
Aryl hydrocarbon receptor (AhR), is a ligand-activated transcription factor that
integrates environmental, dietary, microbial and metabolic cues to control various cellular
processes, such as the cell cycle, epithelial barrier function, cell migration and immune
function. AhR was discovered as the receptor that binds with high affinity to 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) and leads to numerous of toxicological outcomes.
In the current study, we discovered a critical role played by AhR, following activation by
TCDD, in modulating a variety of immunological functions through regulation of
epigenetic and microbial pathways. Our data demonstrated that AhR activation triggers
MDSC mobilization from bone marrow to peritoneal cavity which correlated with
increased levels various of chemokines and their receptors and induced epigenetic
changes via modulation of small noncoding RNA molecules and targeted genes. These
MDSCs had high levels of immunosuppressive activity and energy metabolic rate. Also,
our data provided a novel link between gut microbiome alterations and MDSC induction
and function in colon after TCDD administration. Additionally, we provide evidence that
Resveratrol,

a natural

polyphenol

compound is

capable to

attenuating the

immunotoxicological effect of TCDD by altering the migration, differentiation, and
suppressive function of MDSCs. Together, our studies demonstrate that AhR can be
targeted to suppress inflammation and thus treat inflammatory and autoimmune diseases
as well as cancer.
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CHAPTER 1
INTRODUCTION
1.1: ARYL HYDROCARBONE RECEPTOR (AhR)
Aryl hydrocarbon receptor (AHR) is a member of basic helix-loop-helix/PerArnt-Sim (bHLH/PAS) family of transcription factors that need ligand to be activated (1).
The early studies about AhR were carried out in rat liver and described AhR as enzyme
induced by foreign chemicals and inducible cytochrome P450 (CYP) monooxygenases
(2, 3). However, AhR interacts with foreign chemicals (xenobiotics) but also plays a
critical role in the regulation of immune functions.

Use of Ahr(−/−) knockout mouse

lines provided strong evidence of the wide importance of AhR in various critical-life
processes (4).
AhR has numerous agonists ncluding xenobiotic such as TCDD, PCDDs, PCB,
and 3-MC and non-xenobiotic such as Resveratrol, I3C, and l-Kynurenine. AhR, exists
as a multiprotein complex, containing three molecules of the chaperone protein hsp90 (a
heat shock protein of 90 kDa), the X-associated protein 2 (XAP2), and p23 (23-kDa cochaperone protein). Following xenobiotic agonist binding, the complex translocates to the
nucleus and AhR is dimerized with a related nuclear protein called Arnt and converts
AhR into high affinity DNA binding form. AhR:Arnt complex binds to Dioxin Response
Element (DRE) or Xenobiotic Response Elements (XRE) a specific DNA recognition
site found on the promoters of various genes, thereby regulating the expression of these
genes, such as CYP1A1 (5). In addition to XRE and DRE, AhR can also be recruited to
1

novel target DNA sequences by interaction with estrogen receptor, retinoic acid receptor
(RAR) and retinoblastoma protein (RB) through Krüppel-like factor 6 (KLF6),
controlling the expression of genes that do not bear XREs in their regulatory regions (6).
The important role of AhR in regulation of innate and adaptive immunity was
performed by studies that used AhR knockout mice or mice carrying AhR variants with
reduced affinity for its ligands (7-9). T helper (TH) cell subsets exhibit differential levels
of AhR expression. Th17 cells and regulatory T (Treg) cells (including FOXP3+ Treg
cells and T regulatory type 1 cells (Tr1 cells)) express the highest AhR levels, whereas
naive CD4+ T cells, Th1 and Th2 cells exhibit no or negligible AhR expression (10, 11).
In DC, AhR may contribute to the anti-inflammatory effects of certain cytokines such as
TGF-β that increase Treg cell induction (12), or increase FOXP3 Treg generation (13).
Various studies in last decade have focused on Ahr role in gut specific intestinal
epithelial cells (IECs). AhR plays important role in IEC regeneration following infectious
or chemical injury (14). IEC-specific Ahr knockout (Vil1CreAhrfl/fl) mice failed to control
infection by the pathogen Citrobacter rodentium due to impairment of intestinal stem
cells (ISCs) differentiation into IECs which caused uncontrolled proliferation of these
cells and increased

malignant epithelial cell transformation (14). In addition, Ahr

enhances epithelial barrier function and prevent infection through increase in the
expression of tight junction proteins in response to IL-22 that is produced by DCs and
CD4+ T cells (15, 16), or through controlling the expression of antimicrobial proteins
such as regenerating islet-derived protein 3β (REG3β) and REG3γ and limiting the
pathogenicity of infections in colitis animal models (17).
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1.2: MYELOID DERIVED SUPPRESSER CELLS (MDSC)
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of
immature and mature myeloid cells exhibiting immunoregulatory activity in both arms of
immune system, innate and adaptive immunity (18). The major population of bone
marrow (BM)-derived myeloid cells are granulocytes and mononuclear cells (monocytes,
terminally differentiated to macrophages and dendritic cells (DCs). In the steady
condition, macrophage widely expand in situ, while DCs differentiate from their specific
BM precursors (19). Under physiological conditions, the cell-signaling molecule GMCSF drives myelopoiesis. G-CSF induces granulocyte differentiation and M-CSF induces
macrophage differentiation (20). In chronic inflammation and cancer, these cell-signaling
molecules are enhanced and induce MDSCs generation and expansion (21).
In mice, MDSCs consist of two phenotypes, Monocytic (M-MDSCs) are defined
as CD11b+Ly6G–Ly6Chi cells with low side scatter, and Granulocytic (G-MDSCs) or
Polymorphonuclear (PMN-MDSCs) that can be defined as CD11b+Ly6G+Ly6Clow cells
with high side scatter (22). M-MDSCs have more suppressive function than PMNMDSCs (23). Both of these phenotypes use different mechanism for suppression, The
most distinct factors involved in MDSC suppressive activity include ARG1, ARG2, NO,
upregulation of ROS (23-25). A recent study showed inhibition of fatty acid-β oxidation
(FAO) used by tumor-infiltrating MDSCs as a primary source of energy, impaired the
suppressive function of tumor-infiltrating MDSCs thereby leading to enhanced the
immune response against cancer (26).
It has been reported that there are two groups of interconnected signals involved
in MDSCs accumulation and activation. First group of signals is responsible for
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immature myeloid cell expansion whereas, the second group of signal is responsible for
their activation and promotion of pathologic activity (27). First group includes GM-CSF,
M-CSF, G-CSF, IL-6, VEGF and polyunsaturated fatty acids and signals primarily via
STAT3 and STAT5. However this signaling alone is not sufficient without second
activating signal which is mainly provided by pro-inflammatory molecules such as
interferon-γ (IFN-γ), IL-1β, IL-4, IL-6, IL-13, tumor necrosis factor (TNF), TLR ligand,
and signals that utilize NF-κB, STAT1, and STAT6 transcription factors for their
activation (27-29).
Numerous studies have been addressed that the proliferation, development,
migration and function of MDSCs are controlled by epigenetic mechanisms such as DNA
methylation which enhanced promoter methylation of DNMT3a and DNMT3b and
improved ARG1 and STAT3 expression with THC treatment (30, 31). Histone
modification, one of the epigenetic mechanisms, specifically histone deacetyltransferases
(HDACs), including HDAC2 (32) and HDAC11 also plays a role in MDSC induction
(33). In physiological conditions, miRNA regulate genes expression that is implicated in
cell development and differentiation. Several miRNA have been reported that modify
gene expression and enhance the suppressive function of MDSCs including miR-210,
miR-494, miR-155, miR-21, and miR-34a (34-37).
1.3: 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN (TCDD)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a typical epitome for a group of
environmental halogenated aromatic hydrocarbon contaminants which elicit immune
toxicity and other toxic responses through activation of aryl hydrocarbon receptor (AhR).
TCDD is infused into the environment by many sources including chemical industries
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and burning processes. It is considered a byproduct of fossil fuels and wood combustion.
Also, it is one of the manufacturing remnants of chlorinated hydrocarbons, paper, pulp
bleaching (38). International Agency for Research on Cancer, WHO and US National
Toxicology Program classified TCDD as human carcinogen (39). TCDD is similar to
other chlorinated compounds and has bioaccumulation feature in food chain which causes
food contamination. Ingestion the contaminated food is the most known way to TCDD
exposure (40).
Thymic atrophy is the hallmark of TCDD-mediated immunotoxicity in different
animal models. It is characterized by a marked reduction in the frequency of double
positive (CD4+CD8+) thymocytes, as well as a relative increase in the frequency of
double negative (CD4−CD8−) and single-positive of both CD4+ and CD8+ thymocytes,
these shifts in thymocyte subset frequencies was accompanied by a significant decrease
in the absolute number of thymocytes in each of the four subpopulations (41-44). It was
noted recently that thymic atrophy is also caused by activation Ahr in CD11c+ dendritic
cells which may be responsible for TCDD-induced alterations in the development and
differentiation of thymocytes (45). TCDD also suppresses the activation and
differentiation of human B cells into Immunoglobulin-M (IgM) secreting cells (46, 47).
Activation AhR by its high affinity ligand TCDD in CD4+ T cells directly alters
gene expression and increases IL-10 producing and eventually T-cell differentiation to
FoxP3– type 1 regulatory T cells (Tr1 cells) (48). TCDD through AhR activation, induces
FoxP3+ Treg which promote tolerogenic phenotype and suppress
mediated diseases (13, 49-51).
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several immune-

In humans, ingestion of contaminated food is one of the most common source of
TCDD exposure route (40). The gastrointestinal tract is the largest habitat of microbiota.
The diversity of microbes within a given host can be defined as the number and
abundance of distribution of distinct types of organisms such as bacteria, archaea,
protists, fungi and viruses, which have been linked to immunologic, hormonal, and
metabolic homeostasis of their host. Microbiome dysbiosis occurs due to a wide range of
causes such as diseases, environmental contamination, diet, and stress (52-54). Emerging
studies reported that TCDD after exposure is rapidly absorbed from the gastrointestinal
and causing shift in gut commensals (55, 56).
1.4: 3,5,4'-TRIHYDROXYSTILBENE (RESVERATROL)
Resveratrol (RSV) is a natural polyphenolic products that is synthesized as a
phytoalexin (compounds that are produced in plants as a defense mechanism against
pathogenic and stressful environmental situations) in plants such as grapes, soy, nuts, and
chocolate (57). The chemical structure of resveratrol (trans-3,5,4′-trihydroxystilbene) is
identified in two isomeric forms, cis- and trans-resveratrol, both of isomeric forms have
different biological activities (58). Because of anti-inflammatory, antioxidant,
antibacterial, and anticancer properties of resveratrol, it has received recently significant
scientific attention.
Plurality of anti-inflammatory features of RSV have been investigated widely in
inflammatory bowel diseases, when 5-20 mg/kg of RSV doses reduced colitis symptoms
by decreasing the production of inflammatory cytokines IL-1β, IL-12, IL-6, TNF-α,
COX2, and prostaglandin D2 (PGD2) and increased the levels of IL-10 in rat colitis
models (59-61). Numerous studies from our lab showed the protective role of RSV in
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various inflammatory disease including lung injury (62, 63), kidney injury (64), liver
injury (65), and colitis (66, 67). Also, RSV showed a marked protective effect on
inflammatory and autoimmune disease such as allergic asthma (68), and multiple
sclerosis (69).
In terms of its antioxidant capability, RSV has an aromatic ring structure and OH
group that provides electrons which help to scavenge free radicals that are generated in
the electron transport chain undergoing oxygen-consuming reaction (70). RSV protects
hippocampal neuron from ROS by its scavenging properties (71). Interestingly, RSV
inhibits QR2, a cytosolic enzyme which enhances the production of damaging ROS and
involved in memory impairment. Inhibition of QR2 reduced hippocampal neuronal cell
death– a brain area involved in learning and memory, in the rat model (72).
RSV is considered antibacterial because it is a molecule that has ability to
interact with more than 20 proteins in eukaryotic organisms including Mycobacterium
smegmatis and Escherichia coli, the interaction is accompanied with inhibition of both
ATP hydrolysis and ATP synthesis functions which stop bacterial growth in media (7375).
RSV was reported to exert multiple anticancer activity in various cancer cell lines
through varied mechanisms. Treatment with resveratrol induced apoptotic cell death by
increasing ROS in the human ovarian cancer cell lines, A2780 and SKOV3 (76). In
gastric cancer cell line BGC823, RSV 200 µM inhibited the viability, migration, and
invasion of cells and suppressed metastasis-associated lung adenocarcinoma transcript 1
(MALAT1) expression, which was overexpressed in gastric cancer cells (77).
Furthermore, RSV inhibited the Interleukin-6 induced SGC7901 cell invasion and matrix
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metalloproteinase activation through inhibition of Raf/MAPK pathway of activation (78).
RSV inhibited lung cancer tumor growth that was induced by injection of LLC tumor
cells in B6 mice through reduction of F4/80+ expressing cells and M2 polarization in
tumors (79). Studies from our lab have shown that RSV reduced colitis and prevented
colon cancer through modulation of CD3(+) T cells that express tumor necrosis factor-alpha and
IFN-gamma or through the up-regulation of SIRT-1 in immune cells in the colon (80, 81).

Studies from our lab have also shown that RSV can serve as a ligand or agonist of AhR,
based on the dose (82)
Hypothesis: In the current study, we tested the central hypothesis that activation
of AhR by TCDD may induce significant alterations in the activation and migration of
MDSCs and that this effect may result from modulation of gut microbiota. Interestingly,
we noted that TCDD induced massive mobilization of MDSCs and MDSC subsets from
bone marrow to peritoneal cavity which was regulated by the miRNA. Also, we found
that TCDD caused gut microbiome dysbiosis, which also played a crucial role in the
induction of MDSCs.

Furthermore, we also observed that RSV attenuated

immunomodulating properties of TCDD by reducing the mobilization, differentiation,
suppressive functions of MDSCs.
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CHAPTER 2
AHR ACTIVATION LEADS TO MASSIVE MOBILIZATION OF MYELOID
DERIVED SUPPERSSOR CELLS (MDSCS) WITH IMMUNOSUPPRESSIVE
ACTIVITY THROUGH REGULATION OF CXCR2 AND MIR-150-5P AND MIR543-3P THAT TARGET ANTI-INFLAMMATORY GENES

2.1 ABSTRACT
TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), an environmental contaminant, is a
potent ligand for Aryl hydrocarbon receptor (AhR). In the current study, we made an
exciting observation that naïve C57BL6 mice exposed intraperitoneally to TCDD showed
massive mobilization of MDSCs in the peritoneal cavity. These MDSCs were highly
immunosuppressive and attenuated Con-A-induced hepatitis upon adoptive transfer.
TCDD administration in naïve mice also led to induction of several chemokines and
cytokines in the peritoneal cavity and serum (CCL2, CCL3, CCL4, CCL11, CXCL1,
CXCL2, CXCL5, CXCL9, G-CSF, GM-CSF, VEGF and M-CSF), and chemokine
receptors on MDSCs (CCR1, CCR5, and CXCR2). Treatment with CXCR2 or AhR
antagonists in mice led to marked reduction in TCDD-induced MDSCs. TCDD-induced
MDSCs had high mitochondrial respiration, glycolytic and ATP rates and exhibited
differential miRNA expression profile.

Specifically, there was significant down-

regulation of miR-150-5p and miR-543-3p. These two miRNAs targeted and enhanced
anti-inflammatory genes, including IL-10, PIM1, ARG2, and STAT3 as well as CCL11
and its receptors CCR3 and CCR5 as wells as CXCR2. The role of miRs in MDSC
activation was confirmed by transfection studies. Together, the current study
9

demonstrates for the first time that activation of AhR in naïve mice triggers robust
mobilization of MDSCs through induction of chemokines and their receptors, and MDSC
activation through regulation of miRNA expression.

AhR ligands include diverse

compounds from environmental toxicants such as TCDD that are carcinogenic to dietary
indoles that are anti-inflammatory. Our studies provide new insights on how such ligands
may regulate health and disease through induction of MDSCs.
2.2 INTRODUCTION
TCDD

(2,3,7,8-Tetrachlorodibenzo-p-dioxin)

is

a

halogenated

aromatic

hydrocarbon found in the environment as a contaminant with immunotoxic and
carcinogenic properties. It is well characterized for its ability to act as a high affinity
ligand for AhR, a member of the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS)
family of transcription factors. In fact, AhR is required for induction of toxicity inasmuch
as mice deficient in AhR are mostly resistant to TCDD-mediated toxicity (83). More
recent studies have demonstrated that AhR may also play a crucial role in regulating
various physiological and developmental processes including the functions of the
immune system (84).
Extensive studies have shown that the immune system is one of most sensitive
targets of TCDD. Multiple mechanistic pathways have been identified to delineate how
AhR activation leads to regulation of the immune system. These include but not limited
to: activation of Fas which expresses DREs leading to induction of apoptosis of activated
T cells (84-87). induction of FoxP3 and Tregs by virtue of the fact that FoxP3 expresses
DREs on its promoter (88, 89). promoting Tregs while suppressing Th17 cells through
decreased methylation of CpG islands of Foxp3 and increased methylation of IL-17
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promoter (50, 85) differential miRNA induction such as decreased expression of miR-31,
miR-219, and miR-490 that targeted Foxp3, and increased expression of miR-495 and
miR-1192 that were specific to IL-17 (90). AhR ligands also include dietary compounds
such as indole-3-carbinol (I3C),3,3’-diindolylmethane (DIM), and resveratrol (37, 82, 9193). The essential amino acid tryptophan, acquired from the diet, also serves as a source
of AhR ligands (94). It is interesting to note that while some AhR ligands are considered
to be highly toxic and carcinogenic, others constitute ligands that are endogenously
produced or found in the diet that regulate immune response in health and disease. Also,
while some AhR ligands such as TCDD are known to trigger Tregs, others such as 6formyl indolo[3,2-b]carbazole (FICZ), induce Th17 cells (89, 90). Thus, the precise
mechanisms through which AhR ligands regulate the immune response needs further
investigation.
Myeloid-Derived Suppressor cells (MDSCs) are heterogeneous populations
derived from bone marrow and comprised of myeloid progenitors that under normal
conditions, differentiate into dendritic cells, granulocytes, and macrophages (95). In
situations involving chronic infection, inflammation, trauma or malignancy, the
associated chemokines and cytokines induce abnormal accumulation of such immature
myeloid cells that are highly immunosuppressive (96). These cells in mice express
CD11b+ and Gr-1+ surface markers (97, 98). MDSCs have contradictory roles in infection
and immunity. They may act as a double-edged sword during the early and late stages of
infection and inflammation, from promoting innate immunity in early stages to
attenuating the immune system through inducing immunosuppressive conditions in late
stages of infection (99). In some cases, increasing MDSCs during infection help to reduce
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inflammatory extension and limit undesirable tissue damages (100). In cancers, MDSC
accumulation can prevent anti-cancer immunity thereby facilitating the tumor growth.
MDSCs have also been shown to induce Tregs and regulate macrophage (101, 102).
2.3 MATERIALS AND METHODS
Experimental Animals:
Female mice C57BL/6 mice (6-8) weeks old were purchased from Jackson
laboratory, USA. All mice were housed in specific pathogen-free condition at the
AAALAC-accredited University of South Carolina, School of Medicine, Animal
Resource Facility. All experiments performed using mice were approved by the
Institutional Animal Care and Use Committee (IACUC), University of South Carolina.
Chemicals and reagents
TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences &
Technology, Texas A&M Health Sciences Center, College Station, Texas). RSV was
purchased from Supelco (MO, USA). Concanavalin A (Con A), N acetyl-cysteine (NAC),
AhR antagonist (CH223191) and CXR2 antagonist (Sch527123) were purchased from
Sigma-Aldrich, N.C. Culture medium reagents (RPMI 1640, Penicillin-Streptomycin,
HEPES, L-Glutamine, FBS, and PBS) were purchased from Invitrogen Life Technologies
(Carlsbad, CA). The following antibodies were used for surface markers, and/or intranuclear staining and were purchased from BioLegend (San Diego, CA-USA): FITC or
Alexa Fluor 700-conjugated anti-CD11b, PE or BV510-conjugated-GR-1, Alexa Fluor
488-conjugated anti-Ly6C, BV785-conjugated anti-Ly6G, PE or BV785-conjugated antiCD4, PE-conjugated anti-CD3, and BV510-conjugated anti-NrP1. PE-conjugated anti-IL17, BV605-conjugated anti-IL-10, BV650-conjugated anti-INF-g, PerCP-Cy™5.5-
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conjugated anti-TGF-β, and Alexa Flour 488-conjugated anti-IL-4, Alexa Fluor 488conjugated anti-FOXP3 and PE-Dazzle-conjugated anti-Helios. Fc Blocker reagent was
procured from BD Biosciences (San Diego, USA). Monoclonal Mouse IgG anti Arg1
were purchased from BD Biosciences (San Diego, USA). Monoclonal Rat IgG antibodies
of CD11b and Ly6G/Ly6C (GR-1) were purchased from R&D Systems Biotech Brand
(Minneapolis, USA). Cytofix/CytopermTM Fixation/ Permeabilization kit was purchased
from BD Biosciences (San Diego, USA). True-Nuclear™ Transcription Factor Buffer Set
was from BioLegend. EasySep™ PE Positive Selection Kits were purchased from Stem
cells Technologies (Vancouver, BC, Canada). RNeasy and miRNANeasy Mini kits,
miScript primer assays kit, and miScript SYBR Green PCR kit were obtained from
QIAGEN (QIAGEN, Valencia, CA). The following reagents: iScript and miScript cDNA
synthesis kits were purchased from Bio-Rad (Madison, WI). Epicentre’s PCR premix F
and Platinum Taq DNA Polymerase kits from Invitrogen Life Technologies (Carlsbad,
CA). ELISA kits for IL-4, IL-10 and TGF-b (ELISA MAXTM Standard SET Mouse)
were bought from BioLegend. XFp glycolytic rate assay kit and XFP cell mito stress test
kit were purchased from Agilent Technologies.
Induction of MDSCs in mice by TCDD.
Groups of 5 mice were injected intraperitoneally (i.p.) with TCDD (1-10µg/kg) or
the vehicle, corn oil. At various days post exposure, mice were euthanized, peritoneal
cells were collected, and washed twice with PBS. The cells were counted and stained for
MDSC markers (CD11b and Gr-1), Granulocytic MDSCs (G-MDSCs: CD11b and Ly6G), and Monocytic MDSCs (M-MDSCs: CD11b and Ly6-C) populations by flow
cytometry (BD FACScelesta), as described (103). Feces were collected from two groups
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as well as from naïve group and kept in -80 0C for later use. For RSV treatment, mice
were given orally 50 mg/kg RSV prior one day from TCDD 10 µg/kg injection, upon one
day of TCDD exposure, cells from peritoneal cavity were collected and stain with
MDSCs and MDSCs subset phenotype markers.
Purification of MDSCs and their subsets M-MDSCs and G-MDSCs
TCDD-induced MDSCs were purified from exudates of peritoneal cavity, as
described previously (31). In brief, peritoneal exudates were collected from TCDDexposed mice and labeled with PE-conjugated Gr-1 antibody. PE-selection kit from Stem
Cells Technologies was used for selection and following the protocol from company.
After purification, flow cytometry (BD FACScelesta) was used to assess the purity of
MDSCs. We purified M-MDSCs and G-MDSCs subsets of MDSCs using FACS Aria II
sorter (BD FACS Aria II). Peritoneal exudate cells were stained with CD11b and LY6C
for M-MDSCs or CD11b and LY6G for G-MDSCs.
AhR and CXCR2 antagonists
Mice were injected i.p with 10 mg/kg or 50 mg/kg of AhR antagonist
(CH223191) or CXCR2 antagonist (Sch527123) respectively, one day before TCDD
injection. Peritoneal exudates were collected in day 3 and stained with CD11b, Gr-1,
LY6G and LY6C to detect MDSCs and subset of MDSCs.
Effect of TCDD-induced MDSCs and MDSCs subsets (M-MDSCs and G-MDSCs)
on T-cell proliferation in vitro
To examine the suppressive effect of MDSCs on T-cell proliferation, splenocytes
(5x105) from C57BL/6 naïve mice were cultured in the presence of Con-A (2µg/ml)
together with different ratios of TCDD-generated MDSCs, M-MDSCs and G-MDCSs for
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24 hrs, as described (104). [3H]thymidine (1µCi/well) was added to the cells cultures and
after 18 hrs, radioactivity was measured using a liquid-scintillation counter (MicroBeta
Trilux; PerkinElmer Life and Analytical Sciences).
Mitochondrial respiration, glycolytic rate, and ATP rate.
Oxygen consumption rates (OCR), proton efflux rate (PER), and ATP rate were
measured in 2×105 of purified MDSCs from peritoneum of vehicle or TCDD-treated mice
using XF Extracellular Flux Analyzer (Seahorse Bioscience). For OCR, MDSCs were
plated in XF cell culture plate coated with 15 μg CellTak (BD Biosciences) in XF assay
medium supplied with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose. MDSCs
were analyzed under stressed conditions and in response to 1 μM oligomycin, 1 μM
fluorocarbonyl-cyanide-phenylhydrazone (FCCP), and 0.5 μM rotenone and antimycinA. For PER, MDSCs were plated in XF cell culture plate coated with 15 μg CellTak in
phenol red-free Base Medium enriched with 2 mM glutamine, 10 mM glucose, 1 mM
pyruvate, and 5 mM HEPES as initial conditions. Cells monitored under stressed
conditions and in response to 0.5 µM Rotenone plus Antimycin A (Rot/AA) and 50 mM
2-Deoxy-D-glucose (2-DG). For ATP rate, MDSCs were plated in XF cells culture plate
with 15 μg CellTak in DMEM Medium enriched with10 mM of glucose, 1 mM of
pyruvate, 2 mM of glutamine. ATP rate production measured under stressed conditions in
response to 1.5 µM of oligomycin and 0.5 µM Rotenone + Antimycin A. All three tests
quantified by Seahorse Bioscience XFp Extracellular Flux Analyzer (Agilent
Technologies).
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Proliferation assessment by BrdU and Ki67 labeling in vivo
To characterize MDSCs proliferation in vivo, mice were injected with BrdU (100
mg/kg) two hours before TCDD treatment, as described (105, 106). Cells from the
peritoneal exudate were harvested and were first stained using anti-mouse antibodies
against CD11b and Gr-1. After fixation and permeabilization, the cells were stained with
PerCP-Cy™5.5-conjugated anti-BrdU (BD Biosciences) and PE-conjugated anti-Ki67
antibodies (Biolegend) and using intranuclear staining protocol (BD Biosciences). Quadstained cells were analyzed by flow cytometry (BD FACScelesta).
Con-A-induced hepatitis and adoptive transfer of MDSCs
To generate hepatic inflammation, (C57BL/6) mice were injected intravenously
(iv) with Con-A (12.5mg/kg) as described (103). For adoptive transfer, Con-A injected
mice received 5 million purified MDSCs from peritoneal cavity (PC-MDSCs) or bone
marrow MDSCs (BM-MDSCs) from TCDD-treated mice 1 hr before Con-A injection. In
experiments where TCDD was tested for its ability to attenuate ConA-induced hepatitis,
mice received TCDD (10 µg/kg) by i.p. route, 1 hr before ConA injection. Mice were
sacrificed after 48 hrs post treatment and spleens and livers were harvested as well as
blood was collected. Single cell suspension of splenocytes was prepared and infiltrating
mononuclear cells in the liver were isolated using Percoll gradient, as described (107).
Harvested cells from spleens and liver mononuclear were stained with Abs against CD4
and INF-ƴ or IL-17 or IL-4 or IL-10 to determine Th1, Th-17, Th-2 and induced T-reg
cell populations by flow cytometry (Beckman Coulter). IL-4 and TGF-b cytokines level
were detected in sera by ELISA.
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Enzyme-linked immunosorbent assay (ELISA)
Serum from individual mouse was collected and the concentration of various
cytokines including, IL-4, and TGF-β was measured using ELISA MAXTM Standard
SET Mouse kit for respective cytokines were purchased from Biolegend.
Chemokines analysis
Serum and peritoneal exudates were collected from individual mouse after 3 days
of TCDD or vehicle injection. G-CSF, GM-CSF, M-CSF, Eotaxin (CCL11), LIF, LIX
(CXCL5), KC (CXCL1), MCP-1 (CCL2), MIP-1A (CCL3), MIP-1B (CCL4), MIP-2
(CXCL2), MIG (CXCL9), RANTES (CCL5), and VEGF concentrations were determined
by using Milliplex map kit (Sigma-Milipore, USA)

according to the manufacturer

protocol and analyzed by Bio-Plex chemiluminescence assay system (Bio-Rad).
Histopathology of liver
Livers were harvested from mice and fixed in formaldehyde (4%) overnight, then
embedded in paraffin and cut to ~6 micron-thickness. The liver sections were then
stained with hematoxylin and eosin (H&E) and analyzed by Cytation5 microscopic
system (BioTek, USA).
microRNA Arrays and Analysis
miRNA analysis was carried out as describe (31). Total RNA including
microRNA was isolated from peritoneal MDSCs post-TCDD administration using
miRNAN easy kit from Qiagen and following the protocol of the company (Qiagen).
miRNAs arrays were performed using Affymetrix miRNA array (version 4). Signal
expression (fold change) of more than 3000 miRNAs were detected from the raw array
data and only those miRNAs that were altered more than 2-fold, were considered for
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further analysis. The selected miRNAs were further analyzed for their targets and
alignments using TargetScan, microRNA.org, and miRNAWalk database. Furthermore,
selected miRNAs were analyzed for their role in various diseases and pathways using
Ingenuity pathway analysis (IPA) software. miRNAs from various groups were also
analyzed for their relationship using LucidChart or Venn Diagram.
Real-Time (Q-PCR) to validate miRNAs and associated genes expression
Q-PCRs were performed to determine the expression of selected miRNAs
(miRNA-150-5p, and miRNA-543-3p) on cDNAs synthesized from total RNAs including
miRNAs isolated from peritoneal MDSCs post-TCDD or vehicle exposure. miScript
primer assays kit (QIAGEN, Valencia, CA) and SSo advance SYBR Green PCR kit from
Bio-Rad,were used and Q-PCR was performed following the protocol of the company.
For Q-PCR run conditions to detect miRNA: 15min at 95°C (initial activation step),
followed by 40 cycles of 15s at 94°C (denaturing temperature), 30s at 60°C (annealing
temperature), and 30s at 70°C (extension temperature and fluorescence data collection)
were used.

Normalized expression (NE) of miRNAs was calculated using NE ¼

2_DDCt, where Ct is the threshold cycle to detect fluorescence. The data were
normalized to miRNAs against internal control miRNA (SNORD96A, Qiagen-Germany)
and fold change of miRNAs was calculated against control miRNA (SNORD96A) and
treatment group (TCDD) was compared with vehicle group.
Real time PCR (RT-PCR) to determine the expression of IL-10, ARG2, STAT3,
INOS1 and PIM1 in MDSCs post-TCDD or vehicle treatment.
RT-PCR was performed to detect IL-10, ARG2, STAT3, PIM1, CCL11, CCR1,
CCR3, CCR5, and CXCR2 expression. Primers of these genes are specifically designed
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to above genes through IDT tools (Table 2.1). RT-PCR was performed for 40 cycles
using the following conditions: at 98°C (denaturing temperature) for 30 s, at 98°C
(annealing temperature) for 10 s, and at 60°C (extension temperature) for 30 s. The PCR
products, generated from mouse gene-specific primer pairs, were visualized with UV
light performing electrophoresis (1.2% agarose gel). The band intensity of PCR products
was determined using ChemiDoc image analysis system from Bio-Rad (Bio-Rad,
Hercules, CA). The expression of the above genes were normalized against PCR products
generated from mouse housekeeping gene GAPDH (internal control).
Statistical analysis.
GraphPad Prism software version 6.01 (San Diego, CA) was used for statistical
analysis. A standard t-test or multiple t-test with Holm-Sidak’s multiple comparisons
corrections was used when comparing two groups for significance. A one-way or twoway analysis of variance (ANOVA) with post hoc Tukey’s multiple comparisons test was
used to compare between the means of more than two groups. Error bars were expressed
as Mean ± standard error of mean (±SEM), and significance was determined as having a
p value less than 0.05. Each experiment was repeated at least twice with consistent
results.
2.4 RESULTS
TCDD induces MDSCs in mice.
TCDD is a potent agonist of AhR and thus, we used TCDD to test if activation of
AhR leads to induction of MDSCs. To this end, three doses of TCDD (1, 5, and 10 µg/kg
body weight) or vehicle were injected (i.p.) into C57BL/6 mice and peritoneal exudates
collected on day 3 post treatment. The presence of MDSCs in peritoneal cavity was
19

analyzed by staining the cells with fluorophore labeled anti-mouse CD11b and Gr-1
antibodies and using flow cytometry. There was a dose-dependent increase in both the
percentages and numbers of CD11b+Gr-1+ cells in peritoneal cavity (Fig 2.1A-B) of mice
that received TCDD, when compared to mice that received vehicle. Upon analysis of
subsets of MDSCs (monocytic and granulocytic) by staining the cells with Abs against
Ly6C and Ly6G, we observed significant increase in both monocytic MDSCs
(CD11b+Ly6G–Ly6Chi) and granulocytic MDSCs (CD11b+Ly6G+Ly6Clow) following
TCDD treatment, when compared to vehicle controls (Fig 2.1C-D).

However, the

granulocytic MDSCs were significantly more in both the percentages and total numbers
when compared to monocytic MDSCs. To study the time course, we injected mice with
TCDD and collected peritoneal exudates on days 1, 2 and day 3 post-treatment. We
observed significant induction of MDSCs on day 1 and their numbers continued to rise
till day 3 (Fig 2.1E-F). Additionally, on day 3, we noted that the proportion of G-MDSC
induction was significantly more than that of M-MDSCs (Fig 2.1G-H). Together, these
data demonstrated that TCDD induces robust MDSCs in the peritoneal cavity.
TCDD induces MDSCs through activation of AhR
Because TCDD is a potent ligand for AhR, we tested the effect of AhR antagonist
(CH223191) on the induction of MDSCs by TCDD. We found administration of AhR
antagonist significantly reduced the number of MDSCs (Fig 2.2A-B) and MDSC subsets
(Fig 2.2C-D), thereby suggesting that TCDD was inducing the MDSCs, at least in part,
through activation of AhR.
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TCDD promotes the migration of MDSCs from bone marrow to peritoneal cavity
through chemokines induction.
Normal mouse bone marrow contains 20–30% CD11b+ Gr-1+ while their
proportion is much smaller in the spleens (2–4%), and they are absent in the lymph nodes
(95). Thus, we next determined if TCDD was promoting the migration of MDSCs from
the bone marrow. To this end, we enumerated CD11b+ Gr-1+ cells in bone marrow and
peritoneal exudate at 0 hr and 16 hrs post-TCDD treatment, by flow cytometry
(FACScelesta).

Interestingly. there was a significant decrease in the percentage of

CD11b+ Gr-1+ cells in bone marrow after 16 hrs following TCDD treatment while there
was a significant increase in MDSCs in peritoneal cavity (Fig 2.3A-B). These data
suggested that CD11b+ Gr-1+ cells from the bone marrow may be migrating to the
peritoneal cavity, the site of TCDD administration. Next, we investigated if specific
chemokines have a role to recruit MDSCs from bone marrow to peritoneal cavity. To
that end, we detected some chemokines and cytokines that regulate MDSCs, and found
that the peritoneal fluid of TCDD-injected mice had significant levels of MCP-1 (CCL2),
MIP-1A (CCL3), MIP-1B (CCL4), Eotaxin (CCL11), KC (CXCL1), MIP-2 (CXCL2),
MIG (CXCL9), VEGF, and M-CSF when compared to controls.

Also, we saw an

increase in CCL2, CCL4, CXCL1, CXCL5, G-CSF and GM-CSF in the serum of TCDDtreated mice (Fig 2.3C-D). We also assessed chemokines receptors expression in MDSCs
post-TCDD treatment. We found that three of the chemokine receptors increased in
TCDD-induced MDSCs group (CCR1, CCR5, and CXCR2) when compared to vehicleinduced MDSCs group (Fig 2.3E). Next, we investigated if blocking CXCR2 would have
an effect on MDSCs recruitment to peritoneal cavity. To this end, we injected CXCR2
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antagonist Sch527123 in mice one day before TCDD treatment and after 3 days, MDSCs
were assessed in peritoneal cavity. We observed that MDSC percentage and numbers
were dramatically decreased following CXCR2 antagonist treatment when compared to
controls (Fig 2.3F). We also examined whether TCDD induces only the migration of
MDSCs from bone marrow to peritoneal cavity or it also induces MDSCs proliferation in
the peritoneal cavity.

To that end, we injected BrdU in mice 2 hrs before TCDD

treatment. After 48 hrs, we stained the peritoneal cells using fluorophore labeled antimouse CD11b and Gr-1 antibodies as well as intranuclear BrdU, and intracellular Ki67.
We observed no significant difference in BrdU and Ki67 positive cells between vehicle
and TCDD groups demonstrating that TCDD does not induce proliferation of MDSCs in
the periphery (Fig 2.3G).
TCDD-induced peritoneal MDSCs, M-MDSCs, and G-MDSCs mediate suppression
of T cell activation in vitro
Immune suppression is the hall mark feature of MDSCs and thus, to determine if
TCDD-induced MDSCs can suppress T cell activation, we performed T cell proliferation
assays using ConA (2 µg/ml) in the presence or absence of TCDD-induced MDSCs
collected from peritoneal cavity. We observed dose-dependent suppression of T cell
activation in the presence of MDSCs and furthermore, while both G-MDSC and MMDSCs were suppressive, the latter were found to be more effective (Fig 2.4A-C).
TCDD-induced peritoneal MDSCs have high mitochondrial respiration, glycolytic
and ATP rates.
Tumor-infiltrating MDSCs (T-MDSCs) have been shown to have increased
oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), when
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compared to splenic-MDSCs (29). To explore the nature of TCDD-induced MDSCs, we
tested the Oxygen Consumption Rate (OCR) and Proton Efflux Rate (PER) as well as
ATP rate using Seahorse Bioscience XFp Extracellular Flux Analyzer. We observed that
TCDD-induced MDSCs from peritoneal cavity had higher OCR, PER and ATP
production rate in comparison to vehicle- induced MDSCs (Fig 2.4D-F).
TCDD-induced MDSCs protect ConA-induced liver damage in vivo.
Next, we investigated whether TCDD-induced MDSCs are functional in vivo in
suppressing T cell response. We have shown earlier that MDSCs can protect liver from
ConA-mediated hepatitis in vivo (108). To that end, we injected naïve mice with purified
TCDD-induced MDSCs from peritoneal cavity or bone marrow, i.v. followed 1 hr later
with ConA. Spleens and livers of mice treated with peritoneal-MDSCs or BM-MDSCs
were harvested 48 hrs after treatment. Upon histological analysis of liver, there was
reduced liver inflammation in mice that received TCDD-peritoneal-MDSCs, when
compared to mice that received MDSCs from BM (Fig 2.5A). Analysis of alanine
transaminase (ALT) in sera showed significantly reduced ALT level in sera of mice that
received TCDD-peritoneal MDSCs, when compared to mice that received MDSCs from
BM (Fig 2.5B). Moreover, levels of IL-4 and TGF-β (anti-inflammatory cytokines)
increased in sera of mice that received TCDD-peritoneal-MDSCs, when compared to
mice that received BM-MDSCs (Fig 2.5C). These data suggested that TCDD-induced
peritoneal MDSCs are more immunosuppressive in function in vivo, when compared to
bone marrow-derived MDSCs from the same mice.
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TCDD-induced MDSCs reduce inflammation in liver and spleen of ConA induced
hepatitis mice.
To better understand the suppressive effect of TCDD-induced peritoneal MDSCs,
we purified mononuclear cells from livers as well as spleen cells from mice treated with
peritoneal-MDSCs and BM-MDSCs as described in Materials and Methods. The
mononuclear cells and splenocytes were stained to determine Th1, Th17, Th2 and
induced Tregs.

There was significant reduction in CD4+IL-17+ in the liver and

CD4+IFN-γ+ in the spleens of mice treated with TCDD-induced peritoneal MDSCs, when
compared to cells treated with BM-MDSCs. In contrast, there was significant
upregulation of CD4+IL-10+ in the liver and CD4+IL-4+ in the spleens of mice treated
with peritoneal-MDSCs, when compared to cells from mice treated with BM-MDSCs
(Fig 2.5D-E)
TCDD reduces inflammation in ConA-induced hepatitis in mice by generating
MDSCs and Tregs.
To test if TCDD would directly suppress ConA-induced hepatitis and if this is
regulated by MDSCs, we injected mice with TCDD (10µg/kg) or vehicle 1 hr before
ConA (10mg/kg) injection (iv). We noted that TCDD was able to decrease ALT levels
thereby showing protection of liver damage (Fig 2.6A). Next, we stained the spleen cells
and liver mononuclear cells for MDSCs, various T helper cells (Th1, Th2, and Th3), and
Treg subsets (tTreg, pTreg, and Tr1). We observed significant increase in MDSCs and GMDSCs in spleens of mice exposed to TCDD, when compared to mice treated with
vehicle (Fig 2.6B-C). Furthermore, there was significant reduction in the percentages of
CD3+CD4+ cells and Th1 cells and an increase in the percentages of Th2 cells in TCDD-
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treated mice when compared to vehicle-treated mice (Fig 2.6D-G). For Treg and its
subsets (Fig 2.6H), there was significant increase in the percentages of CD4+FoxP+
population (Fig 2.6I) and in the percentages of pTregs, and Tr1, as well as in the
percentage of Th3 cells in spleen of TCDD-treated mice in comparison to vehicle-treated
mice (Fig 2.6K-L). However, the percentages of CD4+FoxP3- (Fig 2.6J) and tTregs (Fig
2.6K) were significantly decreased in mice were treated with TCDD, when compared to
mice treated with vehicle.
TCDD altered miRNAs expression in peritoneal MDSCs.
Our previous studies demonstrated that miRNA play a critical role in MDSC
induction (65). To that end, we investigated the role of miRNA in the induction of
MDSCs by TCDD, by performing miRNA microarray using MDSCs derived from
vehicle or TCDD-treated groups.

There were more than 3195 miRNAs that were

analyzed by arrays (Fig 2.7A) of which the expression of only 141 miRNAs were altered
by greater than two-fold in TCDD-treated groups when compared to vehicle-controls (Fig
2.7A). As shown in Venn diagram, there were 3054 miRNAs that showed no change
(Fig 2.7B), while 97 miRNAs were upregulated, and 44 miRNAs were downregulated
(Fig. 2.7B). Figure 2.7C depicts upregulated (n=97) and downregulated (n=44) miRNAs
in TCDD-induced MDSCs, when compared to vehicle-induced MDSCs. Similarly, Fig
2.7D depicts TCDD-dysregulated (upregulated and downregulated) miRNAs in TCDDinduced peritoneal MDSCs. Furthermore, upon analysis of 141 dysregulated miRNAs
using ingenuity pathway analysis (IPA) software, we observed a direct relationship
between various miRNAs and the target genes including miR-150-5p and the target genes
IL-10 and PIM1, and miR-543-3p and the target genes ARG2 and STAT3 as well as
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CCL11, CCR3, CCR5 and CXCR2 (Fig 2.7E). These data suggested that TCDDmediated alterations in the miRNAs may regulate the expression of various target
molecules such as IL-10, PIMI, ARG2, STAT3, CCL11, CCR3, CCR5 , and CXCR2
that are prominently involved in the induction and functions of MDSCs.
Real-Time (Q-PCR) to validate selective miRNAs and the target genes.
Based on the complementary binding affinity of miR-150-5p with IL-10 and PIMI
genes (Fig 2.8A) and miR-543-3p with ARG2, STAT3, and CXCR2 (Fig 2.8B) as well as
with CCL11, CCR3, and CCR5 (Fig 2.8C), we selected miR-150-5p and miR-543-3p to
validate their expression. Q-PCR data showed significant downregulation of both miR150-5p and miR-543-3p in TCDD-induced peritoneal MDSCs, when compared to
vehicle-induced MDSCs (Fig 2.9A). Next, we examined the expression of target genes
IL-10 and PIM1 (miR-150-5p target genes), ARG2, STAT3, CCL11, and CCR5 (miR154-3p target genes) by performing Q-PCR. We observed significant upregulation all
these genes in TCDD-induced peritoneal MDSCs, when compared to vehicle-inducedMDSCs (Fig 2.9B). These data demonstrated that TCDD-alters the expression of miRNA
in MDSCs which may lead to their induction and functions.
Analysis of miR-150-5p and miR-543-3p and specific targeted genes expression.
To further understand the role of miR-150-5p in IL-10 and PIM1 expression and
miR-543-3p in ARG2, STAT3, CCL11, CCR3, CCR5, and CXCR2 expression, we
performed a series of transfection assays. To that end, MDSCs were mock-transfected or
transfected with mature miR-150-5p, mature miR-543-3p, anti-miR-150-5p inhibitor or
anit-miR-543-3p inhibitor, and cultured for 24hrs. Next, the expression of various
miRNAs and their target molecules was studied. Mock-transfected MDSCs showed basal
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level expression of both miR-150-5p and miR-543-3p. MDSCs transfected with mature
miR-150-5p and miR-543-3p showed significantly upregulated expression of both
miRNAs in transfected MDSCs. However, transfection of MDSCs with anti-miR-150-5p
and ani-miR-543-3p inhibitors showed downregulated expression of both miRNAs in
MDSCs (Fig 2.9C,E). These data demonstrated that transfection of MDSCs with mature
miRNAs or anti-miRNAs inhibitors showed expected results. To further understand the
role of these two miRNAs, we performed q-PCR to determine the expression of IL-10,
PIM1, STAT3, ARG2, CC11 genes and chemokines receptors CCR2, CCR5, and
CXCR2. As shown in Fig 2.9D, the expression of IL-10 and PIM1 was significantly
reduced in MDSCs in the presence of miR-150-5p. However, the expression of the above
genes was significantly increased in MDSCs in the presence of anti-miRNA inhibitor.
Figure 2.9F showed significant reduction in the expression of ARG2, STAT3 as well as
chemokine CCL11 and chemokines receptors, CCR3, CCR5, and CXCR2 (Fig 2.9G) in
MDSCs in the presence of miR-543-3p. However, there was a significant increase in the
expression of these genes and chemokines receptors in the presence of anti-miRNA
inhibitor. Together, these data demonstrated that TCDD-mediated alterations in the
expression of miRNA may play a critical role in MDSC induction and functions.
2.5 DISCUSSION
In the current study we made an exciting observation that TCDD potently
induces MDSCs at the site of administration even in naïve animals. Also, TCDD was
able to induce MDSCs in an inflammatory model of ConA-induced hepatitis. We found
that TCDD-induced MDSCs were highly immuosuppressive as demonstrated using in
vitro and adoptive transfer experiments. TCDD induced both the subsets of MDSCs:
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granulocytic

G-MDSCs

(CD11b+LY6G+Ly6Clow)

and

monocytic

M-MDSCs

(CD11b+Ly6G-LY6Chi). Additionally, we found that TCDD caused alterations in the
expression of miRNA in MDSCs that promote the immunosuppressive functions of
MDSCs.
TCDD is well characterized for its immunosuppressive properties that are
mediated through activation of AhR (109-112). TCDD-mediated immunosuppression
may involve multiple pathways because AhR ligation leads to activation of DREs found
on a significant number of genes (113-115). TCDD-mediated immunosuppression may
involve multiple pathways because AhR ligation leads to activation of DREs found on a
significant number of genes (36-38), including those involved in the regulation of
immune response. Some mechanistic pathways that have been previously identified
include: induction of Fas that expresses DRE on its promoter and upregulation of FasL
leading to enhanced activation-induced cell death/apoptosis (84, 85, 87, 114, 116, 117),
upregulation of FoxP3 which also expresses DREs thereby leading to induction of Tregs
(88, 89) increased induction of Tregs while suppressing Th17 cells via epigenetic
regulation (50), and the like. In addition to Tregs, it is increasingly becoming clear that
MDSCs also play a critical role as regulators of inflammation (103, 118, 119). Whether
AhR activation can lead to induction of MDSCs in naïve mice has not been investigated
thus far, and therefore formed the rationale for the pursuit of the current study.
Interestingly, we found that TCDD treatment led to robust induction of MDSCs in naïve
animals in a dose-dependent manner and such an induction was AhR-dependent. It has
been reported that there are two groups of interconnected signals in MDSCs
accumulation and activation. First group of signals is responsible for immature myeloid
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cells expansion whereas, the second group of signal is responsible for their activation and
promotion of pathologic activity (27). First group includes GM-CSF, M-CSF, G-CSF, IL6, VEGF and polyunsaturated fatty acids and signals primarily via STAT3 and STAT5.
However this signaling alone is not sufficient without second activating signal which is
mainly provided by pro-inflammatory molecules such as interferon-γ (IFN-γ), IL-1β, IL4, IL-6, IL-13, tumor necrosis factor (TNF), TLR ligand, and signals that utilize NF-κB,
STAT1, and STAT6 transcription factors for their activation (27-29). In the current study,
we found that induction of MDSCs in the peritoneal cavity was associated with increases
in several chemokines such as CCL2, CCL3, CCL4, CCL11, CXCL1, CXCL2, CXCL5
and CXCL9. Also, the observation that TCDD caused a decrease in MDSCs in the bone
marrow while an increase in the peritoneal cavity suggested that TCDD-induced
chemokines in the peritoneal cavity may have caused MDSC mobilization from bone
marrow to peritoneal exudate. This was also supported by the observation that TCDD
treatment led to a significant decrease in BM-MDSCs with a consequent increase in
peritoneal MDSCs.

Additionally, we found that the peritoneal MDSCs induced by

TCDD were not actively dividing thereby supporting the migration rather than in situ
proliferation of MDSCs. We noted that TCDD treatment also caused activation of
MDSC and their functions. Energy metabolic pathway(s) used by MDSCs may play a
critical role on the immunosuppressive functions of MDSCs and increase in this pathway
is a sign for high immunosuppressive activity of cells (26). We observed that TCDDinduced MDSCs had higher oxygen consumption rates (OCR), proton efflux rate (PER)
and ATP rate. TCDD-induced MDSCs also exhibited significant increase in cell lineagespecific transcription factors and cytokines including IL-10, PIM1, STAT3, and ARG2.
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Chemokines and their receptors such as CCL5, CXCL17, CXCL2, CCR5 and CXCR2
play a critical role in MDSCs migration from bone marrow to tumor environment (120122). Furthermore, we observed increased expression of chemokines receptors postTCDD administration on MDSCs such as CCR1 (receptor for CCL3 and CCL4), CCR5
(receptor for CCL4 and CCL11) and CXCR2 (receptor for CXCL1, CXCL2 and CXCL5)
(Fig 2.3E). One of the chemokine receptors that is expressed on MDSCs that has
effective role in MDSC migration is CXCR2. Thus, CXCR2-deficient mice showed
significantly decreased MDSC induction, in an inflammatory models of endometriosis
when compared to wild-type mice (123). Also, we found in the current study that
blocking CXCR2 using an antagonist Sch527123, reduced TCDD-mediated MDSC
induction (Fig 2.3F). Importantly, a second signal that is involved in MDSC
accumulation includes GM-CSF, G-CSF, M-CSF, and VEGF (23, 124), and we found an
increase in these factors in both serum and peritoneal exudate of TCDD-treated group
when compared to vehicle (Fig 2.3C-D). These data together suggested that TCDDinduced upregulation of chemokines and their receptors were responsible for the
migration and accumulation of MDSCs in the peritoneal cavity. We were surprised to
see that TCDD induced many chemokines and thus, we checked to see if such
chemokines may be induced following AhR activation involving DREs. To that end, we
performed in silico analysis to address if the chemokine promoters expressed DREs.
Such an analysis demonstrated that several chemokines expressed DREs on their
promoters (Table 2).
MDSCs constitute a heterogeneous population of cells representing a pathological
state of activation of myeloid cells that have acquired a highly immunosuppressive
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phenotype (125). These cells are of great interest in cancer as well as in inflammation as
they potently suppress the cytotoxic activities of natural killer and natural killer T cells,
and immune responses mediated by CD4 and CD8 T cells (120, 126). Under normal
conditions, precursor myeloid cells from bone marrow differentiate into mature
granulocytes, macrophages or dendritic cells as they home to peripheral organs.
However, enhanced mediator production during pathological conditions such as cancer,
infections, trauma, inflammation and autoimmunity, as well as sometimes in response to
certain natural compounds, there is proliferation of immature myeloid cells while
blocking

their

terminal

differentiation

resulting

in

the

accumulation

of

immunosuppressive MDSCs phenotype (121). Recent studies from our laboratory have
demonstrated the induction of MDSCs as an important mechanism through which several
natural compounds exert immunosuppressive or anti-inflammatory properties, including
marijuana cannabinoids, and resveratrol (103, 108, 122, 127)
Functional

analysis

of

TCDD-induced

MDSCs

showed

potent

immunosuppressive effects on T cell proliferation in vitro. We noted that while both GMDSC and M-MDSCs were immunosuppressive against T cell proliferation in vitro, the
latter cells were more potent. In the current study, we also demonstrated that TCDDinduce MDSCs were functionally immunosuppressive in vivo as well.

Thus, upon

adoptive transfer of TCDD-induced MDSCs in to ConA-injected mice, there was
significant protection of liver form acute inflammation. This was found to be associated
with increased polarization of Th2 cells and Tregs and decreased induction of Th1 and
Th17 cells, along with increased production of anti-inflammatory cytokines TGF-β and
IL-4 levels in these mice (Fig 2.5A-E). These data are consistent with our previous
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studies demonstrating that MDSCs induced by cannabinoids can suppress ConA-induce
hepatitis in vivo upon adoptive transfer (103). Importantly, we also noted that
administration of TCDD into ConA-injected mice also led to protection of liver and in
such mice, we also saw similar cell phenotypes including increased presence of MDSCs,
Th2 cells, Tregs, and subsets of Tregs but a decrease in the induction of Th1 cells (Fig
2.6). MDSCs can induce Tregs through disruption Th17/Treg balance because MDSCs
have the potential to convert Th17 cells into Foxp3+ Treg and enhance shifting the
immune response from inflammation to tolerance (128), which can also be mediated by
increase of IL-10 or TGF-β production (101, 129).
Several studies have shown that miRNA play an influential role in the toxicity of
TCDD in animal models (116, 130-133). Studies have also shown that miRNA play a
critical role in the regulation of MDSCs in different diseases models (65, 104, 134-136).
For example, inhibition of miRNA-9 has been shown to promote the differentiation of
MDSCs whereas, overexpression of miRNA-9 markedly enhanced the function of
MDSCs (137). Also miRNA-155 and miRNA-21 were the two most upregulated
miRNAs during the induction of MDSCs from the bone marrow cells by GM-CSF, IL-6
and TGF-B (36). Chen and his colleagues found that miRNA-17-5p, miRNA-20a,
miRNA-223, miRNA-21, miRNA-155, miRNA-494, miRNA-690, and miRNA-101 are
of particular interest for tumor MDSCs accumulation and function (138). In this study,
we also observed that TCDD-induced MDSCs exhibited significant down-regulation in
the expression of miRNA including miR-150-5p and miR-543-3p. Upon further
characterization of these two miRNAs, we observed that these two miRNAs targeted
several anti-inflammatory genes IL-10, PIM1, ARG2, STAT3, and
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CCL11 and

chemokines receptors CCR3, CCR5, and CXCR2. Transfection studies confirmed that
these miRNAs caused upregulation of these anti-inflammatory genes. IL-10, ARG2, and
STAT3 have been well characterized for their ability to downregulate the production of
pro-inflammatory cytokines such as INF-γ, IL-2, IL-3, and TNF-α (122, 127).
Additionally, STAT3, a transcription factor, is a hallmark of MDSCs, as STAT3 is
directly involved in the accumulation and expansion of MDSCs in humans and mice.
Arg2 found in MDSCs is directly involved in depleting l-arginine availability for T cells
in the inflamed microenvironment and thus inhibit T-cell proliferation. MDSCs not only
suppress T cell activation by IL-10 production but also by interacting with macrophages
to increase IL-10 production and decrease IL-12 secretion (139-141). PIM1 is a member
in serine/threonine kinases family that has two members, PIM2 and PIM3 in addition to
PIM1 and have been implicated in the regulation of apoptosis, metabolism, cell cycle,
and migration. PIMI was observed to be overexpressed in numerous solid tumors and was
accompanied by MDSCs accumulation (142). From the current study, we noted that
CCL11 and its receptors CCR3 and CCR5 were specifically embroiled in MDSCs
migration from bone marrow to peritoneal exudate. Analysis using ingenuity pathway,
shed light on the relationship of STAT3, IL-10, PIM1, ARG2, CCL11, CCR3, CCR5, and
CXCR2 and the two downregulated miRNAs, miR-150-5p that targets IL-10 and PIM1
and miR-543-3p that targets ARG2, STAT3, CCL11, CCR3, CCR5, and CXCR2.
In summary, the present study demonstrates for the first time that activation of
AhR triggers massive accumulation of MDSCs even in naïve mice without any
inflammatory signal, resulting from induction of chemokines and their receptors.
Furthermore, we observed that TCDD also causes changes in the expression of miRNA
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within the MDSCs and alter gene expression that promote their anti-inflammatory
functions. AhR activation is a double-edged sword. On one hand AhR plays a key role
in intestinal homeostasis.

Thus, deficits in AhR signaling have been linked to

experimental and human intestinal bowel disease (143). On the other hand, AhR ligands
such as the environmental contaminants, TCDD or methylcholanthrene (3-MC), are
highly toxic and are considered to be carcinogens. Interestingly, this dual-action of AhR
activation also correlates with that of MDSCs which are known to suppress inflammation
and autoimmune disease (144) as well as promote tumor development and progression
(145). Further studies aimed at addressing the nature of AhR-induced MDSCs in the
regulation of health and disease should provide useful clues to regulate disease
pathogenesis.
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Figure 2.1: TCDD induces MDSCs in naïve mice. Naïve C57BL/6 mice were injected
with TCDD or vehicle i.p. and at various days post-treatment, cells from the peritoneal
cavity were harvested and analyzed for MDSCs. (A) Representative plots from flowjo
software analysis of flow cytometry data showing induced in MDSC percentages
following 1, 5, or 10 µg/kg TCDD administration when compared to vehicle. Cells were
harvested on day three (B) Total number of MDSCs/mouse expressed as mean+/-SEM
based on panel A description (C) Representative pseudocolor plots showing Monocytic
MDSCs (CD11b+LY6G-LY6Chi) and Granulocytic MDSCs (CD11b+LY6G+LY6Clow)
percentages following administration of 1, 5, or 10 µg/kg TCDD when compared to
vehicle. (D) Total number of monocytic and granulocytic MDSCs/mouse expressed as
mean+/-SEM. (E) Time-course of induction of MDSCs. (F) Total number of
MDSCs/mouse at different days expressed as mean+/-SEM. (G) Representative plots
showing M-MDSCs and G-MDSCs after 3 days of 10 µg/kg TCDD treatment when
compared to vehicle. (H). Total number of MDSCs/mouse after 3 days following 10
µg/kg TCDD administration, expressed as mean+/-SEM. Statistical analysis was
performed using Student’s t test and one-way analysis of variance (ANOVA) *p < 0.05;
**p < 0.01; ***p < 0.001; ****p <0.0.0001.
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Figure 2.2: AhR
antagonist CH223191 treatment decreases TCDD-mediated
MDSC induction. Naïve C57BL/6 mice were injected with TCDD (10 µg/kg) i.p. as
described in Fig 1 legend. These mice were injected i.p with 10 mg/kg of AhR antagonist
(CH223191) one day before TCDD injection. Peritoneal exudates were collected in day 3
and stained for MDSCs. (A) Representative flow cytometric analysis showing MDSC
percentages after treatment with AhR antagonist. (B) Total number of MDSCs/mouse
expressed as mean+/-SEM following treatment with AhR antagonist, based on panel A
description. (C) Representative flow cytometric analysis showing percentages of MDSC
subsets after treatment with AhR antagonist. (D) Total number of MDSC subsets /mouse
expressed as mean+/-SEM following treatment with AhR antagonist. One-way analysis
of variance (ANOVA) was used to compare between the groups *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001.
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Figure 2.3: Identifying the source of TCDD-induce MDSCs. Naïve C57BL/6 mice
were injected with TCDD (10 µg/kg) i.p. as described in Fig 1 legend. (A)
Representative flow cytometric analysis showing that percentage of MDSCs in bone
marrow 16 hrs after TCDD treatment when compared to 0 hr. Contrary, MDSCs
percentage increased in peritoneal cavity after 16 hrs compared to 0 hr. (B) Total number
of MDSCs/mouse expressed as mean+/-SEM based on panel A description (C)
Measurement of chemokines in peritoneal exudate with data expressed as mean+/-SEM.
(D) Detection of chemokines in the serum with data expressed as mean+/-SEM. (E) QPCR validation of CCR1, CCR5 and CXCR2 expression in TCDD compared to vehicle,
with data expressed as mean+/-SEM. (F) Flow cytometric analysis of MDSC percentage
and absolute numbers following treatment with TCDD and CXR2 antagonist. Vertical
bars represent total cellularity/mouse expressed as mean+/-SEM. (G) Representative
plots of BrdU labeling and anti-Ki67 staining at 48 h post-TCDD treatment. The left
panel shows staining for MDSCs and right panel shows staining for BrdU and Ki67 on
gated MDSCs. Vertical bars represent mean ± SEM. Student’s t test and One-way
analysis of variance (ANOVA) with *p < 0.05; **p < 0.01; ***p < 0.001; ****p<0.0001.
.
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Figure 2.4: TCDD-induced MDSCs suppress T cell proliferation and exhibit
different metabolic profile. (A-C) TCDD-induced purified peritoneal MDSCs as well as
monocytic and granulocytic MDSCs were incubated with spleen cells activated with
ConA at different ratios and T cell proliferation was assessed by 3H-thymidine
incorporation assay. Data are depicted as mean ± SEM of triplicate cultures shown as
counts per minute (CPM). (D,E) Oxygen consumption rate (OCR) and Glycolytic proton
efflux rate (GRE) TCDD-induced MDSCs compared to vehicle-induced MDSCs. (F).
ATP production rate in the experimental groups. Student’s t test was used to compare
between the groups in panels A-C **p < 0.01; ***p < 0.001.
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Figure 2.5: TCDD-induced MDSCs protect from ConA-induced liver damage and
inflammation in vivo following adoptive transfer. C57BL/6 mice were injected
intravenously with Con-A (12.5mg/kg) and these mice received 1 hr before, adoptive
transfer of 5 million purified MDSCs from peritoneal cavity (PC-MDSCs) or bone
marrow MDSCs (BM-MDSCs) from TCDD-treated mice. Mice were sacrificed after 48
hrs post treatment for further analysis. (A) H&E stain of liver tissue. (B) Measurement
of ALT in sera. (C) Measurement of TGF-4 level in sera. Percentages of cells
expressing various cytokines determined by flowcytometry in spleen(E), and liver (F).
Vertical bars represent mean ± SEM. Student’s t test *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2.6: TCDD treatment attenuates ConA-induced hepatitis and associated
inflammation. ConA was used to induce hepatitis as described in Fig 5 legend. These
mice received TCDD (10 µg/kg) by i.p. route, 1 hr before ConA injection followed by
analysis of spleens and liver for inflammation. (A) ALT level in serum of hepatitisinduced mice treated with vehicle or TCDD. (B, C) Percentage and total numbers of
MDSCs and G-MDSCs in the spleens of two groups respectively. (D, E) Percentage of
CD3+CD4+ cells in the spleens, respectively. (F,G) Percentages of Th1 and Th4 cells in
splenocytes showing data from a representative and multiple experiments, respectively.
(H-L) Elucidation of T-regs and their subsets in spleen cells showing both a
representative experiment and data from multiple experiments in the form of vertical
bars. Vertical bars represent mean ± SEM. Student’s t test **p < 0.01, ***p < 0.001.
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Figure 2.7: TCDD-mediated alterations in miRNA expression in MDSCs. Naïve mice
were treated with TCDD as described in Fig 1 legend. The peritoneal MDSCs were
analyzed for miRNA expression. (A) Heat map of miRNAs expression in MDSCs from
vehicle and TCDD groups showing more than 3000 miRNAs. (B) Venn diagram showing
miRNA that are up or down regulated in TCDD group when compared to vehicle
controls. (C) Heat map of up and down regulated (greater than two-fold) of miRNAs in
vehicle vs TCDD groups. (D) IPA ingenuity software analysis was used to determine
interaction between up- and down-regulated miRNAs and targeted genes.
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Figure 2.8: SVR and context alignment between miRNAs and targeted genes. (A,B)
SVR score and alignment (miRNA.org) between mir-150-5p and targeted genes (IL-10
and PIM1) as well as between mir-543-3p and targeted genes (ARG2 and STAT3). (C)
Context score and alignment (targetscan.org) between mir-543-3p and CCL11, CCR3,
CCR5, and CXCR2.
.
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Figure 2.9: Q-PCR analysis of miRNA-150-5p and miRNA-543-3p and specific
targeted genes. MDSCs were isolated as described in Fig 1 legend. (A) Expression of
mir-150-5p and mir-543-3p in TCDD-induced MDSCs when compared to vehicle. (B).
Expression of targeted genes IL-10, PIM1, ARG2, STAT3, CCL11, CCR3 and CCR5 in
TCDD-induced MDSCs when compared to vehicle. MDSCs was transfected with mimic
and inhibitor of both mir-150-5p and mir-543-3p (C) mir-150-5p expression with mimic
compared to mock and inhibitor. (D) Expression of IL-10, PIM1 with inhibitor of mir150-5p compared to mock and mimic of mir-150-5p. (E) Expression of mir-543-3p with
mimic compared to mock and inhibitor. (F) Expression of ARG2, STAT3, CCL11,
CCR3, and CCR5 in the presence of inhibitor of mir-543-3p compared to mock and to
mimic of mir-543-3p. Vertical bars represent mean ± SEM. *p < 0.05; **p < 0.01;
***p < 0.001.
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Table 2.1: The forward and reverse primers for listed genes:
Gene

Primer

Sequences (5’-3')

PIM1

Forward

TTCTGGACTGGTTCGAGAGG

Reverse

TGTTCTCGTCCTTGATGTCG

Forward

TGTCATCTGGGTTGATGCTC

Reverse

CAGGAGGCTCCACATCTCTC

Forward

CCCATTCCTCGTCACGATCTC

Reverse

TCAGACTGGTTTGGGATAGGTTT

Forward

CAATACCATTGACCTGCCGAT

Reverse

GAGCGACTCAAACTGCCCT

Forward

GAATCACCAACAACAGATGCAC

Reverse

ATCCTGGACCCACTTCTTCTT

Forward

CTCATGCAGCATAGGAGGCTT

Reverse

ACATGGCATCACCAAAAATCCA

Forward

TCAACTTGGCAATTTCTGACCT

Reverse

CAGCATGGACGATAGCCAGG

Forward

TTTTCAAGGGTCAGTTCCGAC

Arg2

IL-10

STAT3

CCL11

CCR1

CCR3

CCR5
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CXCR2

Reverse

GGAAGACCATCATGTTACCCAC

Forward

ATGCCCTCTATTCTGCCAGAT

Reverse

GTGCTCCGGTTGTATAAGATGAC
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Table 2.2: Number of the sequences sites of the dioxin responsive element (DRE) on the
promoter region of listed chemokines as well as accession and version for each
chemokine.
Chemokine
or miR

Number of DRE Sequence
Sites

Accession and Version

5'-CACGC-3'

5'-GCGTG-3'

CCL2

1

2

AL626807.7

CCL3

1

2

AL596122.14

CCL4

1

2

AL596122.14

CCL11

2

2

AL645596.7

CXCL1

1

4

AC157938.9

CXCL2

2

5

AC157938.9

CXCL5

2

2

AC105995.9

CXCL9

3

4

AC109603.8

CXCR2

3

0

AC117757.23

miR-150-5p

19

11

AC126256.4

miR-543-3p

6

8

AC121784.2
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CHAPTER 3
AHR ACTIVATION LEADS TO ALTERATIONS IN THE GUT MICROBIOME
WITH CONSEQUENT EFFECT ON INDUCTION OF MYELOID DERIVED
SUPPRESSER CELLS IN A CXCR2-DEPENDENT MANNER

3.1 ABSTRACT
Aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor and
2,3,7,8-Tetrachlorodibenzo-p-dioxin

(TCDD),

a

well-documented

environmental

halogenated aromatic hydrocarbon, is a potent ligand for AhR. Thus, AhR activation by
TCDD leads to significant immunomodulation. Recent studies have shown that immune
system homeostasis is also maintained by gut microbiota.

Thus, whether TCDD-

mediated regulation of immune response occurs through cross talk with gut microbiota is
unclear. Previously, we observed that activation of AhR by TCDD in C57BL6 mice
leads to massive mobilization of myeloid derived suppresser cells (MDSCs).

In the

current study, we observed that TCDD caused significant alterations in gut microbiome,
specifically, increasing the abundance of several Prevotella and Lactobacillus at the
genus level while decreasing Sutterella and Bacteroides. Fecal material transplantation
(FMT) from TCDD-treated donor mice into antibiotic treated (ABX) mice induced
MDSCs and MDSC subsets as well as increased Tregs. Injecting TCDD directly into
ABX mice also induced MDSCs but to a much lesser degree than in naïve mice. These
data suggested that TCDD-induced dysbiosis plays a critical role in MDSC induction.
Interestingly, treatment with TCDD led to induction of MDSCs in the colon and
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undetectable levels of cysteine.

MDSCs suppressed T cell proliferation while

reconstitution with cysteine restored this response. Lastly, blocking CXCR2 impeded
TCDD-mediated MDSC induction. Our data demonstrate that AhR activation by TCDD
triggers dysbiosis which in turn regulates, at least in part, induction of MDSCs.
3.2 INTRODUCTION
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an environmental pollutant
generated during the manufacture of herbicides or burning organic materials such as
waste incarnation, fossil fuel, and wood combustion (146). Ingestion of contaminated
food is one of the most common exposures of TCDD in humans (40). Following TCDD
exposure, immune cells such as regulatory T cells (Tregs) are expanded and effector Tcells are suppressed (147), in addition to depletion of macrophages and dendritic cells in
jejunum (148, 149). A single dose of oral TCDD administration decreased
immunoglobulin (Ig) A secretion in the gut by impairing B-cell function (150). The gut
is lined with a single layer of epithelia cells connected by tight junction proteins and is
interspersed with mucus-secreting goblet cells and paneth cells which release
antimicrobial peptides (151). Interestingly, mice treated orally with TCDD developed
tolerance to ovalbumin (OVA) and showed suppression in the humoral immune response
in the epithelial cells of lumen, as well as serum and fecal samples (152). However, in
these same studies, alterations of other immune cells e.g. CD4+, CD8+, CD19+, and
CD103+MHCII+CD11c+ by TCDD occurred only in the gut-specific draining lymph node
(MLN).
The diversity of microbes within a given host can be defined by the number,
abundance, and distribution of distinct types of organisms such as bacteria, archaea,
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protists, fungi and viruses. The interaction and activity of these microbes has been linked
to the homeostasis of immunologic, hormonal, and metabolic processes of the host.
Microbial dysbiosis and alterations in the microbiome with negative effects on the host,
occurs due to a wide range of causes such as diseases, environmental contamination, diet,
and stress (52-54). The gastrointestinal tract is the largest habitat of the microbiota, and
emerging studies have shown that TCDD exposure leads to its rapid absorption into the
gastrointestinal tract which can cause shifts in gut microbiome commensals (55, 153).
Nonetheless, whether there is a link between immunological changes induced by TCDD
and the gut microbiota has not been previously studied.
Most of the activity of TCDD is mediated through the aryl hydrocarbon (AhR), a
cytosolic-bound receptor expressed in a variety of immune cells including T-cells,
monocytes, granulocytes, myeloid-derived suppressor cells (MDSCs), and mast cells.
AhR activation by TCDD leads to alterations in the immune system involving several
mechanisms such as disruption of the Treg/Th17 balance, suppression of the cytotoxic
T-cells response, impairment of antibody production by B cells in a T cell dependent
manner, and decrease in IL-6 and TNF production by macrophages, and induction of
apoptosis in activated T cells (50, 87, 114, 154-156). TCDD is also well-characterized
for its ability to induce Tregs (50, 157). Recently, we observed that TCDD administration
leads to massive induction of MDSCs that are highly immunosuppressive (manuscript
under review). Thus, in the current study, we investigated if the microbiota of the host
plays any role in the induction of MDSCs by TCDD.
Using 16S rRNA sequencing of the gut microbiome, we noted that TCDD
exposure resulted in alterations of the gut microbiome, and metabolome, such as
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reduction in cysteine metabolism. Importantly, using fecal material transfer (FMT)
experiments we found that MDSC induction by TCDD was dependent, at least in part, by
the gut microbiota.
3.3 MATERIAL AND METHODS
Animals
Female C57BL/6 adult mice were purchased from Jackson laboratory (Bar
Harbor, MA). All the animals were housed in the Animal Research Facility (ARF)
located at the University of South Carolina (USC) under pathogen-free conditions. Mice
were cared for in accordance with the NIH guideline for use of laboratory animals under
protocols approved by the university Institutional Animal Care and Use Committee
(IACUC) at USC.
Chemicals and reagents
TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences &
Technology, Texas A&M Health Sciences Center, College Station, Texas). Culture
medium reagents (RPMI 1640, Bacitracin, Gentamycin, Ciprofloxacin, Neomycin,
Penicillin, Metronidazole, Ceftazidime, Streptomycin, and Vancomycin from SigmaAldrich (St. Louis, MO). HEPES, L-Glutamine, FBS, and PBS) were purchased from
Invitrogen Life Technologies (Carlsbad, CA). The following antibodies were purchased
from Biolegend (San Diego, CA) and used for surface markers, intra-cellular and/or intranuclear staining: Alexa Fluor 700-conjugated anti-CD11b, BV510-conjugated-GR-1,
Alexa Fluor 488-conjugated anti-Ly6C, BV785-conjugated anti-Ly6G,

BV785-

conjugated anti-CD4, PE-conjugated anti-CD3, Alexa Fluor 488-conjugated anti-IL-17,
BV605-conjugated anti-IL-10, BV650-conjugated anti-INF-ƴ, BV421-conjugated anti-
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IL-4, BV510- conjugated anti-FOXP3 and, APC-conjugated anti-CD25. FC Block and
monoclonal Mouse IgG anti-Arg1 were purchased from BD Biosciences (San Diego,
USA). Monoclonal Rat IgG antibodies of CD11b and Ly6G/Ly6C (Gr-1) were purchased
from Biolegend (San Diego, CA). Cytofix/CytopermTM Fixation/ Permeabilization kit
was purchased from BD Biosciences. True-Nuclear™ Transcription Factor Buffer Set
was purchased from BioLegend. EasySep™ PE Positive Selection Kits were purchased
from Stem Cell Technologies (Vancouver, BC, Canada). N acetyl-cysteine (NAC) and
CXCR2 antagonist Sch527123 were purchased from Sigma-Aldrich (St. Louis, MO).
Cysteine Assay Kit was purchased from Abcam (Cambridge, United Kingdom).
TCDD Exposure and 16S rRNA amplicon sequencing
Female C57BL/6 between 6-8 weeks were injected i.p. with TCDD (10 µg/kg) or
Vehicle (corn oil), as described previously (116, 158). Feces from individual mouse were
collected from TCDD- or Vehicle-treated mice or from naïve mice, three days post
treatments and kept in -800C for later use. 16S rRNA sequencing and analysis were
performed as previously described (159). QIAamp DNA Stool Mini Kit (Qiagen) was
used for DNA isolation from fecal pellets (100 mg) of the three groups following the
protocol of the company (Qiagen). Genomic DNA samples were quantified by using
nanodrop system (Thermo Scientific) and kept in -800C for further use. Amplification of
the 16S rRNA V3–V4 hypervariable region was carried out using the 16S V3 314F
forward (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGC
WGCAG-3′)

and

V4

805R

GTCTCGTGGGCTCGGAGATGTGTATAAGA,
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reverse

primers

(5′-

GACAGGACTACHVGGGTATCTAATCC-3′).

The

Illumina

overhang

adapter

sequences to be added to locus‐specific sequences are:
Forward overhang: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG
Reverse overhang: 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG
The PCR program used were 3 min at 95°C, followed by 25 cycles of 30 s at 95°C, 30 s
at 55°C, and 30 s at 72°C and a final extension at 72°C for 5 min. Each reaction mixture
(25 μl) contained 50 ng of genomic DNA, 0.5 μl of amplicon PCR forward primer (0.2
μM), 0.5 μl of amplicon PCR reverse primer (0.2 μM), and 12.5 μl of 2× KAPA Hifi Hot
Start Ready Mix. AMPure XP beads were used for each reaction to purify the 16S V3
and V4 amplicon away from free primers and primer dimer species. Attachment of dual
indices and Illumina sequencing adapters was performed using the Nextera XTIndex Kit
includes 5 μl of amplicon PCR product DNA, 5 μl of Illumina Nextera XT Index Primer
1 (N7xx), 5 μl of Nextera XT Index Primer 2 (S5xx), 25 μl of 2 × KAPA HiFi Hot Start
Ready Mix, and 10 μl of PCR-grade water. Amplification was carried out under the
following program: 3 min at 95°C, followed by 8 cycles of 30 s at 95°C, 30 s at 55°C,
and 30 s at 72°C, and a final extension at 72°C for 5 min. Constructed 16S metagenomic
libraries were purified with AM Pure XP beads and quantified with Quant-iTPicoGreen.
Libraries were quantified using a fluorometric quantification method that uses dsDNA
binding dyes. DNA concentration was calculated in nM based on the size of DNA
amplicons as determined by an Agilent Technologies 2100 Bioanalyzer trace. Libraries
were normalized and pooled to 40 nM based on quantified values. Pooled samples were
denatured and diluted to a final concentration of 8 pM with a 30% PhiX (Illumina)
control. Samples then were loaded, and results were provided by MiSeq Reporter
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software (MSR). The Metagenomics workflow classifies organisms from V3 and V4
amplicon using a database of 16S rRNA data. The classification is based on the
Greengenes database (http://greengenes.lbl.gov/). The output of this workflow is a
classification of reads at several taxonomic levels: kingdom, phylum, class, order, family,
genus, and species. The online 16S analysis software from the National Institutes of
Health (Nephele) was used to analyze sequencing data collected on the Illumina MiSeq.
The groups of related DNA sequences were assigned to operational taxonomic units
(OTUs), and output files were analyzed to determine gut microbial composition. The
Phylogenetic Investigation of Communities by Reconstruction of Unobserved States
(PICRUSt) option during Nephele analysis was used to examine differences Level 2 (L2)
and Level 3 (L3) KEGG pathways using collected 16S rRNA sequencing data. In order to
differentiate significant alterations within the gut microbiome from experimental
samples, linear discrimination analysis of effect size (LeFSe) was used as previously
described (160).
Short chain fatty acid (SCFA) analysis
SCFAs were quantified as previously described by Mehrpouya-Bahrami et al
(161). In brief, 100 mg cecal contents were acidified by metaphosphoric acid and allowed
to sit on ice for 30 min. After centrifugation of acidified samples at 12,000xg for 15 min
at 40C, supernatants were collected and filtered using MC filters at 12,000xg for 4 min in
40C. MTBE (400 µL) from Sigma (650560) was added to each sample after transferring
samples in to glass vials. The samples were then centrifuged down at 1300 rpm for 5 min
at RT and the top organic layer was transferred to a new vial. The standard mixtures with
the internal standard were used to determine the response factors and linearity for each
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SCFA standard acid.

A HP 5890 gas chromatograph configured with the flame-

ionization detector (GC-FID) for analysis of volatile organic compounds was used to
detect the concentration of propionic, n-butyric, isovaleric, valeric, isobutyric, caproic,
and n-heptanoic acid in the samples.
Depletion of the gut microbiota
Depletion of the gut microbiome was achieved using a cocktail of antibiotics
(ABX) consisting of

the following: Bacitracin 1 mg/ml, Gentamycin 170 µg/ml,

Ciprofloxacin 125 µg/ml, Neomycin 100 µg/ml, Penicillin 100 U/ml, Metronidazole 100
µg/ml, Ceftazidime 100 µg/ml, Streptomycin 50 µg/ml, and Vancomycin 50 µg/ml, as
previously described (96, 162, 163) ABX treatment lasted for 24 days and was supplied
in the drinking water. Feces for transfer experiments were collected from individual
mouse under sterile conditions. To validate microbiome reduction, DNA was isolated
using QIAamp DNA Stool Mini Kit (Qiagen) and analyzed by performing agarose gel
electrophoresis. DNA Fragments were visualized by Imaging Chemi-Blots on the BioRad ChemiDoc XRS HQ. Band density of DNA from ABX-treated mice were compared
to band density of DNA from WT control mice. In addition, swabs from ABX-treated
mouse and control feces were cultured in aerobic and anaerobic conditions 2 days. ABX
treatment was stopped on day 25, and mice to be inoculated with fecal material were cohoused with Vehicle and TCDD donors on day 26, followed by all subsequent treatments
given to mice on day 27.
Fecal material transplantation (FMT)
FMTs were performed to determine the effects of TCDD on the gut microbiome
after TCDD treatment. Donor mice were divided into two groups (n=8 per group). One
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group was injected with 10 µg/kg i.p. injections of TCDD (T), and the second group was
treated with corn oil as the vehicle (V). After 3 days, colon contents were collected under
sterile and anaerobic conditions for dilution in sterile PBS. ABX-treated mice were
divided into 5 groups (n=4-5 per group) and treated as follows:

untreated, treated

butyrate in their drinking water (1% sodium butyrate), with TCDD (10 µg/kg) (TCDD);
with FMTs from vehicle treated mice (VFMT); FMT from TCDD-treated mice (TFMT).
The mice were euthanized after three days using isoflurane overdose to collect cells from
peritoneal exudates, spleens, and blood.
Flow cytometry to evaluate immune cell phenotypes
MDSCs and MDSCs subsets were stained and identified as described by us
previously (103). Cells were harvested from peritoneal cavity of recipient and treated
mice and stained with fluorescently-labeled antibodies (Biolegend and BD Biosciences)
for phenotyping. Antibodies included Alexa Fluor 700-conjugated anti-CD11b, BV510conjugated-Gr-1, Alexa Fluor 488-conjugated anti-Ly6C and BV785-conjugated antiLy6G BioLegend (San Diego, CA, USA) to determine MDSCs (CD11b+Gr-1+) and the
following MDSC subsets: monocytic MDSCs (CD11b+Ly6G–Ly6Chi) and granulocytic
MDSCs (CD11b+Ly6G+Ly6Clo). For T helper and transcription factor FOXP3 staining,
antibodies used were BV785-conjugated anti-CD4, PE-conjugated anti-CD3, Alexa Fluor
488-conjugated anti-IL-17, BV605-conjugated anti-IL-10, BV650-conjugated anti-IFN-γ,
BV421-conjugated anti-IL-4, and BV510-conjugated anti-FOXP3 to detect the following
T helper (Th) subsets: Th1 (CD3+CD4+IFN-γ+), Th2 (CD3+CD4+IL-4+), Th17
(CD3+CD4+IL-17+), and Tregs (CD4+FoxP3+). Flow cytometry analysis was performed
using BD FACs Celeste and FlowJo software from ThermoFisher Scientific.
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Real-Time (RT-PCR)
DNA was isolated from feces of experimental groups using QIAamp DNA Stool
kit from Qiagen (Valencia, CA), and samples were diluted to 1ng/µl concentrations.
MiScript primer assays kit and miScript SYBR Green PCR kit from Qiagen were used to
perform PCRs following the protocols provided by the company. Sutterella and
Lactobacillus PCR primers were purchased from IDT Technologies with primer
sequences based on previous publications (164, 165). Cystathionase, XCT, 4F2 and ASC
primers were designed based on a

previous publication (120). The PCR products,

generated from mouse gene-specific primer pairs or bacteria-specific primers pairs, were
visualized with UV light performing electrophoresis (1.2% agarose gel). The band
intensity of PCR products was determined using ChemiDoc image analysis system from
Bio-Rad (Bio-Rad, Hercules, CA). The expression of the above genes were normalized
against PCR products generated from mouse housekeeping gene GAPDH or against PCR
product generated from Eubacteria gene (internal controls) as previously reported (67).
Purification of MDSCs
TCDD-induced MDSCs from the exudates of peritoneal cavities were purified as
previously described using selection of Gr-1+ MDSCs (119). In brief, peritoneal exudates
were collected from TCDD-exposed mice and after washing the cells two times with
PBS, cells were labeled with a PE-conjugated Gr-1 antibody from Biolegend and
magnetically sorted using a Positive Mouse PE Selection kit from Stem Cell
Technologies (Cambridge, MA) following instructions from the manufacturer.
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[3H] thymidine incorporation assay
To measure the proliferation of T-cells, splenocytes (5x105) from C57BL/6 naïve
mice were cultured in the presence of Con A (2 µg/ml) in medium deficient in N-acetylcysteine (NAC) or with NAC (0.5 Mm) in a 96-well round bottom plate. The cells were
cultured alone or cultured together with TCDD-induced peritoneal MDSCs in the ratio of
1:0.5 overnight. [3H] thymidine (1 µCi/well) was added to the cell cultures, and after 18
hrs radioactivity was measured using a MicroBeta Trilux liquid-scintillation counter
(PerkinElmer Life and Analytical Sciences).
Detection of Cysteine level in peritoneal exudate, and colon exudate
Cysteine concentration was assessed in peritoneal and colon exudates collected
from mice that received TCDD treatment using a fluorometric Cysteine Assay Kit
(ab211099) from Abcam following the protocol from the manufacturer. Delta
corresponding fluorescence values (∆ RFU) were calculated and applied to the cysteine
standard curve to calculate reaction concentration.
Fluorescence staining of colon tissue sections
Colon

tissue

samples

from

three

groups

(Vehicle,

TCDD,

and

TCDD+Sch527123) were fixed in 4% paraformaldehyde diluted in PBS overnight. Fixed
colons were sectioned (5 µm thick) and placed on coated slides. Slides were incubated for
30 min in glycine 0.1% and 1x triton for tissue permeabilization for Arg1 staining or with
glycine 0.1% only for CD11b and Gr-1 staining. Slides were then incubated with primary
mouse anti-Arg1 antibodies or primary rat anti-CD11b and anti-Gr-1 antibodies
purchased from Cell Signaling (Danvers, MA) at 40 C overnight, followed by a 2 hour
incubation at room temperature with secondary Alexa Fluor 488 goat anti-mouse IgG
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antibody for Arg1, Alexa Fluor 488 goat anti-rat IgG for CD11b, and Cy5 goat anti-rat
IgG antibody for Gr-1. Fluorescent imaging of colon sections was taken using a Leica
DM 2500 optical microscope from Leica Microsystems (Buffalo Grove, IL).
Quantification of cell markers was calculated as corrected total cell fluorescence (CTCF)
using Image J software (National Institutes of Health and the Laboratory for Optical and
Computational Instrumentation).
Statistical analysis
GraphPad Prism software version 6.01 (San Diego, CA) was used for statistical
analysis. Student's t-test was used for paired observations if data followed a normal
distribution to compare between two groups while one-way analysis of variance
(ANOVA) was used to compare between more than two groups. A P-value of ≤0.05 was
considered statistically significant. For all experimental results, data was collected from
at least two independent experiments with consistent results unless otherwise stated.
3.4 RESULTS
TCDD exposure alters the gut microbiome composition and SCFA production
TCDD is a well characterized high affinity ligand for AhR and therefore, we used
TCDD to investigate how AhR activation alters the gut microbiota.

16S rRNA

sequencing with the Illumina MiSeq platform was performed on feces from the following
groups: wild-type mice (Naïve), mice treated with corn oil (Vehicle), and mice given
10µg/kg i.p. injections of TCDD (TCDD). Data collected from sequencing showed that
Vehicle or TCDD treated mice had decreased alpha diversity when compared to naïve
controls, which was assessed by Chao1 rarefaction measurement (Fig. 3.1A). Beta
diversity from principle coordinate analysis (PCoA) also showed that Vehicle and TCDD
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treated mice had gut microbial compositions dissimilar to Naïve mice, however, all
groups clustered in their own respective treatment niches, suggesting TCDD-treated mice
had a distinct composition when compared to Vehicle (Fig. 3.1B). However, sequencing
data and OTU classification from the phylum to genus level showed that TCDD
treatment had a marked effect on gut microbiome composition (Fig. 3.2-6).
In order to differentiate the significantly altered bacteria between all the
experimental groups, LEfSe analysis was performed on the OTUs from phylum to genus.
Results showed that there were several bacteria found to be distinctly expressed in the
Naïve, Vehicle, and TCDD groups. These included the genus Bacteroides, Sutterella,
Prevotella, and Lactobacillus (Fig. 3.1C-D). Among this LEfSe-identified bacteria,
significantly altered OTUs between Vehicle and TCDD-treated mice included Prevotella,
Sutterella, Lactobacillus, and Bacteroides (Fig. 3.1D). Specifically, after TCDD
exposure, there was a significant increase in abundance of several Prevotella and
Lactobacillus at the genus level however, Sutterella and Bacteroides were significantly
decreased. To confirm the sequencing results, we quantified bacteria abundance from
feces of experimental groups using bacteria-specific primers by PCR. These results
confirmed that there was a significant increase (> 4 fold change) of Lactobacillus in
TCDD-treated groups when compared to Naive and Vehicle groups (Fig. 3.1F). In
addition, PCR validation experiments confirmed that there was a significant reduction in
Sutterella (~50%) in TCDD-exposed mice (Fig. 3.1G). The phylogenetic sequencing and
PCR validation data clearly demonstrated that TCDD exposure caused alterations in the
microbiome, such as changing the abundance of Lactobacillus and Sutterella populations
in the gut.
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In addition to the phylogenetic data, bacterial metabolomic SCFA production was
evaluated in the fecal samples from experimental mice exposed to TCDD. Of all the
SCFAs studied, only two were found to be significantly altered after exposure to TCDD,
which included acetic acid and butyric acid. Mice injected with TCDD showed
significant increases in both acetic acid and butyric acid (Fig. 3.1H) when compared to
Naïve control or Vehicle-treated mice. Taken altogether, these results showed that TCDD
exposure leads to not only changes in the microbial phylogeny in the gut, but also alters
some SCFA production as well.
TCDD-induced fecal microbiota when transferred into ABX mice can trigger
MDSCs and Tregs.
TCDD exposure has been shown to regulate the immune response, particularly in
suppressing the inflammatory T cell-mediated response (50, 166). Recently, we found
that activation of AhR by TCDD induces large numbers of CD11b+Gr-1+ MDSCs in
peritoneal cavity of mice (manuscript under consideration), as also shown (Fig 3.7A
upper panels and 3.7B), which included both granulocytic-MDSCs and monocyticMDSCs (Fig 3.7C upper panels and 3.7D). To further understand the role of microbiota
in TCDD-mediated MDSC induction, FMT experiments were performed in ABX-treated
mice. After confirming ABX treatment led to depletion of the gut microbiome (Fig. 3.8),
various treatments and FMT experiments were performed to evaluate the contribution of
the microbial changes to MDSC induction. This included fecal microbiota transfer (FMT)
from Vehicle-treated mice into ABX mice (VFMT+ABX) or from TCDD-treated mice
into ABX mice (TFMT+ABX).

Interestingly, we observed that TFMT+ABX mice

displayed higher proportion as well as increased numbers of MDSCs when compared to
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VFMT+ABX mice (Fig. 3.7A lower panels, and 3.7B). Also, these MDSC induced in
TFMT+ABX mice included both G-MDSCs and M-MDSCs (Fig 3.7C lower panels, and
3.7E). The FTM experiments were repeated with consistent results (Fig 3.9). These
results strongly suggested that the gut microbiome plays a role in TCDD-mediated
induction of MDSCs. Moreover, when we injected TCDD directly into ABX mice, we
were able to induce MDSCs (Fig 3.9), although it was not as robust as injecting TCDD
into naïve mice (Fig 3.7A upper panels) thereby showing that normal microbiota seen in
naïve mice does play a role in MDSC induction by TCDD. We also injected butyrate
into ABX mice to see if that would induce MDSCs and failed to detect any increase (Fig
3.9). The data that FMT from TCDD-treated mice into ABX mice could induce MDSCs
and that TCDD could induce only a weak MDSC response in ABX mice, together
demonstrated that induction of MDSCs by TCDD was dependent, at least in part, on gut
microbiota.
AhR activation by TCDD, as well as MDSCs have been shown to induce Tregs
(167, 168). To investigate if transplanted feces from TCDD-treated mice was able to
induce Tregs, we harvested spleen cells from ABX-treated mice given TFMT or VFMT.
We observed that TFMT mice did not exhibit any significant change in CD3+CD4+ cell
numbers (Fig 3.10A-B) but interestingly, showed an increase in the numbers of
CD4+FOXP3+ Tregs (Fig 3.10C-D). These data showed that induction of Tregs in naïve
mice by TCDD may also depend, at least in part, on microbiota.
TCDD reduces cysteine level in colon and peritoneal exudates
In addition to phylogenetic data obtained from Nephele of the 16s rRNA
sequencing data, theoretical analysis of the gut microbiome metabolomic profile was
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determined using PICRUSt (Fig. 3.11A). Results from this in silico analysis assigning
OTUs to KEGG pathways showed that TCDD caused a significant reduction in cysteine
and methionine metabolism (Fig. 3.11B). To validate these findings, expression of
cysteine-related genes were evaluated using PCR. Results showed that compared to
Vehicle-induced peritoneal MDSCs, TCDD-induced peritoneal MDSCs express less
cystathionase (CTH), the enzyme responsible for converting intracellular methionine to
cysteine (Fig. 3.11C), as well as plasma membrane ASC (alanine-serine-cysteine
transporter) neutral amino acid transporter and Xc- and its light (XCT) and heavy chain
(4F2) components, which are responsible for exporting cysteine and importing cystine
from environment (Fig. 3.11C). Upon analysis of cysteine levels in the peritoneal and
colon exudates of treated mice, it was found that cysteine levels were undetectable in
mice exposed to TCDD, while Vehicle groups showed significant levels (Fig. 3.11D). In
order to determine the role cysteine plays in MDSC function, proliferation assays were
performed using ratios of MDSCs and T cells in the presence or absence of cysteine. As
shown in Fig. 3.11E, upon activation with ConA adding cysteine in the media reduced
the suppressive effect of MDSCs on the T-cells (Fig. 3.11E). These data demonstrated
that TCDD exposure significantly impacted cysteine metabolism and this in turn has
effects on the ability of MDSCs to suppress the activated T cell response.
TCDD-mediated effects on MDSCs and the gut microbiome are dependent on
CXCR2
CXCR2 is a chemokine receptor important in the recruitment of MDSCs (169).
Therefore, we investigated the effect of blocking CXCR2 on TCDD-mediated MDSC
induction in the colon and peritoneal cavity. To test this notion, 50 mg/kg of CXCR2

62

antagonist, Sch527123, was injected in mice one day before treatment with TCDD. Colon
sections from experimental mice were taken 3 days after TCDD exposure and stained
with MDSC-specific markers (CD11b, Gr-1 and Arg1). Results showed that CD11b, Gr1, and Arg1 expression increased in the colon after injection with TCDD when compared
to colons from Vehicle-treated mice but this increase was lost in mice treated with the
CXCR2 antagonist (Fig. 3.12A-D). Results also showed that blocking CXCR2 prevented
the accumulation of MDSCs in the peritoneal cavity after injecting with TCDD (Fig.
3.12E-F). Taken together with the FMT results, these data suggested that TCDDmediated effect on MSDCs is dependent on CXCR2.
3.5 DISCUSSION
In the last past several decades, numerous studies have shown that exposure of
laboratory animals to TCDD leads to profound immunosuppression (109-112). More
recent studies have shown that AhR activation by TCDD can suppress the immune
system in mice by way of induction of Tregs (9, 49). Previous studies from our lab have
also shown that TCDD was able to attenuate the clinical and inflammatory markers of
colitis (50). The gut microbiome consists of trillions of bacteria which are sensitive to
many endogenous and exogenous factors including diet, age, health condition, life style,
and environmental exposures (170). A fundamental role of microbiome in the induction,
education, and function of the host immune system is therefore understandable. In a
mutually reciprocal relationship, microbial colonization in the host gut affects the
development of the immune system, but also subtle changes in the immune system has
effects on the gut microbiome composition (171). There are few studies on how AhR
activation or exposure to TCDD can directly or indirectly cause changes in gut
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microbiota, bile acids, and short chain fatty acid (SCFA) metabolism (172, 173). Previous
studies have shown that TCDD, when given orally to mice, caused a shift in mouse gut
commensals (56, 174). TCDD was even shown to play a role in influencing a shift
favoring bacteria that expressed antimicrobial resistance genes (ARGs) (153).
In the current study, we observed significant alterations in the gut microbiome 3
days after exposure to TCDD. These alterations were characterized by reductions in
certain bacteria, such as Sutterella, while significant increases in the abundance of other
bacteria were observed, such as Lactobacillus.

Some studies have reported that a

decrease in Sutteralla and an increase in Lactobacillus are related to immune tolerance.
Tang et al. observed that a reduction in Alcaligenaceae and Sutterella levels in normal
mice after feeding with purple sweet potato polysaccharides caused an increase in antiinflammatory cytokines IL-2 and IL-6 (175). Similarly, Pena et al. found significant
reductions in pro-inflammatory IFN-γ and TNF-α in the spleen of probiotic-treated mice
using a mixture of Lactobacillus paracasei and Lactobacillus reuteri, which resulted in
lessening the severity of colitis in IL-10-deficient mice infected with Helicobacter
hepaticus (176).
Alterations in gut microbiome, also leads to changes in bacterial metabolome,
such as the production of SCFAs. SCFA, like acetic acid, butyric acid, and propionic
acid, are metabolic end products of undigested complex carbohydrates for bacterial
fermentation in the colon (177). We observed that the level of two SCFAs, butyric acid
and acetic acid, were significantly higher in mice exposed to TCDD. Butyrate is known
to exhibit tolerance-inducing activities such as induction of Treg cells, as well as other
anti-inflammatory activities to include increased production of IL-22 (178). Several
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studies, both in vivo and in vitro, have demonstrated that SCFA inhibit of histone
deacetylases (HDACs), which results in many cases in the inactivation of nuclear factorκB (NF-κB) and downregulation of a number of pro-inflammatory cytokines, like tumor
necrosis factor (TNF) (179, 180). In addition, increased SCFA could enhance the
differentiation of peripheral Treg populations through HDAC9 inhibition, and
consequently attenuation of colitis in mice (181). Gallausiaux et al. also show butyrate
produced by gut commensal bacteria influence the proportion and activation of antiinflammatory regulatory T cells (Treg) (182). Given this information, the increase in
SCFAs like butyrate after TCDD exposure could explain some of the mechanisms which
drive the immune suppression of this environmental pollutant. However, we found that
direct administration of butyrate into ABX mice failed to induce MDSCs.
Mammalian cells, including immune cells, require the essential amino acid
cysteine for protein synthesis and proliferation (183, 184). Cysteine is generated by cells
through two distinct pathways. One involves reducing intracellular disulfide-bonded
cystine which is imported through plasma membrane transporter Xc- to form cysteine,
which is eventually exported through the plasma membrane ASC transporter. Another
pathway involves converting intracellular methionine to cysteine if the cells synthesize
cystathionase enzyme. T cells does not express Xc- and ASC however, and thus, they
depend on antigen presenting cells (APCs) such as macrophage and dendritic cells to
obtain cysteine (185-189). MDSCs sequester cystine and do not export cysteine because
they express only Xc-. Therefore, a large number of MDSCs in the microenvironment
creates competition for cysteine between MDSCs and other immune cells, which can lead
to reduction in cysteine levels, causing the suppression of T cell proliferation (120). In
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the current report, TCDD reduced cysteine and methionine metabolism as evidenced
through examination by PICRUSt, and these results were validated showing cysteine
levels in the peritoneal cavity and colon exudates were decreased after TCDD exposure.
The reason behind cysteine reduction after TCDD exposure could be attributed to
sequestering by MDSCs, or it could also be attributed to an increase in bacteria, such as
Lactobacillus, which use cysteine as a sulfur source to grow (190). It was thus interesting
that when cysteine was provided in culture, it reversed the suppression of T cell
proliferation mediated by MDSCs.
CXCR2 was shown to play a critical role in the induction of MDSCs. CXCR2 has
been shown to play a critical role in MDSC migration to endometrial lesions through
interactions with CXCL1, 2, and 5 (123).

The fact that blocking CXCR2 reduced

MDSCs significantly both in the colon and peritoneal cavity of TCDD-treated mice,
confirmed the important role played by CXCR2 in inducing MDSCs in the colon. In an
earlier study, we noted that TCDD can induce CXCR2 in naïve mice because it expresses
several DREs on its promoter . Thus, AhR activation by TCDD involving DREs on
CXCR2 gene promoter may help induce CXCR2 which in turn triggers MDSCs.
In summary, the current report provides evidence that TCDD causes a shift in the resident
gut microbiome, particularly through increasing Lactobacillus and decreasing Sutterella
abundances. FMT experiments confirmed that TCDD-mediated changes in the gut
microbiome altered the immune system, specifically by increasing the MDSCs in a
CXCR2-dependent manner, which resulted in decreased cysteine levels. Such events may
promote an immunosuppressive response, thus providing evidence that AhR activation by
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TCDD alters the microbiome in such a way that it influences the immune system of the
host.
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Figure 3.1: TCDD treatment alters microbiome composition. C57BL/6 mice were
treated with TCDD (10 µg/kg) or vehicle and 3 days later, feces were collected for 16S
rRNA sequencing. (A) Rarefaction curves depicting alpha diversity within groups (Chao1
index) of naïve (n=7), vehicle (n=6) and TCDD-treatment groups (n=6) are shown. (B)
Three-dimensional principle coordinate analysis (PCoA) based on the unweighted
UniFrac distance of all samples for three groups, naïve, vehicle and TCDD. (C) LeFSEgenerated cladogram for OTUs showing the phylum, class, order, family, genus and
species from the outer to inner swirl, respectively. Red indicates enrichment in taxa in
samples from naïve group, blue from vehicle group, and green from TCDD group. (D)
LeFSE-generated LDA scores for differentially expressed taxa. The threshold of LDA
score was set to 3.5. (E) Percentage of OTUs of significantly-altered bacteria at the genus
level. (F-G) q-PCR validation with primers for Lactobacillus (F) Sutterella and bacteria.
(H) Concentration of butyric acid and acetic acid produced by the microbiota in the fecal
contents. Bar graphs consists of vertical bars representing mean ± SEM. One-way
analysis of variance (ANOVA) with Tukey’s multiple comparisons test was used to
determine significance; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.2: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data
depicting relative OTU abundance at the phylum level.
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Figure 3.3: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data
depicting relative OTU abundance at the class level.
.
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Figure 3.4: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data
depicting relative OTU abundance at the order level.
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Figure 3.5: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data
depicting relative OTU abundance at the family level.
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Figure 3.6: Mini blot bar from Nephele analysis showing 16s rRNA sequencing data
depicting relative OTU abundance at the genus level.
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Figure 3.7: Bacterial depletion in ABX mice. Naïve mice were treated with a cocktail
of antibiotics for 3 weeks prior to FMT experiments. (A) UV agarose gel electrophoresis
image of genomic DNA in naïve WT and ABX mice showing PCR expression of
Eubacteria. (B) Relative normalized expression of Eubacteria in WT Naïve or ABX mice
using qRT-PCR (C) UV images of culture plates with swabs from fecal samples from
control, WT Naïve, and ABX mice in aerobic (top) and anaerobic conditions (bottom).
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Figure 3.8: Effect of fecal microbiota transplantation on MDSCs and MDSC subset
induction. Normal mice received Vehicle or TCDD and were analyzed for MDSCs or
MDSC subsets in the peritoneal cavity (upper panels A, C, and panels B,D). Expression
of CD11b and Gr-1 was used for MDSCs and CD11b and LY6C or LY6G for monocytic
and granulocytic MDSCS, respectively. Also, ABX mice received feces from colon from
vehicle (VFMT+ABX) or TCDD-treated mice (TFMT+ABX). And peritoneal cells were
stained for MDSCs or subsets (lower panels A,C and panels B, E). Panels A and C show
percentages of MDSCs while panels B, D, E show absolute number of MDSCs. Vertical
bars represent mean ± SEM. Student’s t test *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001.
For
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Figure 3.9: Effect of TCDD or FMT transfer into ABX mice on MDSC induction in
ABX mice. These experiments were carried out as described in Fig 2 legend. ABX mice
were administered TCDD alone, sodium butyrate alone, FMT from vehicle-treated
(VFMT) or TCDD-treated (TFMT) donor mice. Peritoneal cavity fluid was collected and
stained for CD11b Gr-1 for MDSCs and CD11b LY6C or LY6G for monocytic and
granulocytic, respectively. (A) Representative flow plots of MDSCs (top) and MDSC
subsets (bottom) in the ABX-treated mice given Butyrate, TCDD, VFMTs, and TFMT.
(B-D) Total percentage of MDSCs and MDSC subsets in the ABX-treated mice given
Butyrate, TCDD, and FMTs. Bar graphs consists of vertical bars representing
mean ± SEM.
One-way analysis of variance (ANOVA) with Tukey’s multiple
comparisons test was used to determine significance; *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3.10: Fecal transplantation from TCDD-treated mice to ABX mice leads to
induction of Tregs. FMT was performed as described in Fig 2 legend. Cells from
spleens of VFMT or TFMT recipient mice were processed to stain stained for T cell
markers. (A) Representative flow plot (CD4+CD3+) in spleen cells of ABX recipient
mice following FMT from vehicle (VFMT) or TCDD (TFMT) donors. (B) Total cell
number (CD4+CD3+) in spleen cells of ABX recipient mice following FMT from vehicle
(VFMT) or TCDD (TFMT) donors. (C) Representative flow plot of Tregs
(CD4+FoxP3+). (D) Percentage of Tregs from multiple experiments. Vertical bars
represent mean ± SEM. Student’s t test was used for compression between the two groups
(VFMT vs. TFMT). *p < 0.05; **p < 0.01.
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2
Figure 3.11: Role of cysteine in TCDD-mediated immunomodulation. C57BL/6 mice
were treated with TCDD (10 µg/kg) or vehicle and feces were collected for 16S rRNA
sequencing. (A) PICRUSt data from Nephele depicting KEGG pathways altered in
vehicle (n=6), and TCDD (n=6) gut microbiome. (B) Percent OTUs attributed to
cysteine and methionine metabolism. (C) qPCR quantification of ASC (alanine-serinecysteine transporter) neutral amino acid transporter, XCT (light chain of antiporter Xc-)
and 4F2 (heavy chain of antiporter Xc-) chains; CTH (cystathionase) . MDSCs were
selected by PE selection kit from peritoneal fluid of vehicle or TCDD-treated groups. (D)
Cysteine level quantification in peritoneal and colon exudate in vehicle or TCDD mice.
(E) Representative 3H-thymidine incorporation assay for T-cell proliferation in media
deficient in cysteine or with cysteine. Student’s t test and one-way analysis of variance
(ANOVA) were used to compare between the groups in panels *p < 0.05; **p < 0.01;
***p < 0.001.
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Figure 3.12: Role of CXCR2 in TCDD-mediated induction of MDSCs. Colon samples

from three groups: Vehicle, TCDD, and TCDD with CXCR2 antagonist Sch527123 were
fixed with 4% paraformaldehyde in PBS overnight and then sectioned to 5 µm thickness
on coated slides. Slides were incubated with antibody detection of Gr-1, CD11b, and
Arg1 (A) CD11b Gr-1 fluorescence staining in colon. Colon section from three groups
were stained with CD11b (green) and Gr-1(red) to detect MDSCs. (B) Arg1 fluorescence
staining (green) to quantify Arg1 expression in colon of three groups. (C-D) Statistical
analysis of CD11b Gr-1 and Arg1 expression in colon sections of three groups as
measured in CTCF using image J software. (E) Representative flow plots of MDSCs in
peritoneal fluid in vehicle, TCDD and TCDD with CXCR2 antagonist Sch527123. (F)
Absolute numbers of MDSCs in peritoneal fluid in vehicle, TCDD and TCDD with
CXCR2 antagonist Sch527123. One-way analysis of variance (ANOVA) and Tukey’s
multiple comparisons test were used to compare between the groups. *p < 0.05;
**p < 0.01; ***p < 0.001. ****p <0.0001.
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CHAPTER 4
RESVERATROL-MEDIATED ATTENUATION OF TCDD-INDUCED MDSCS
MOBILIZATION, DIFFERENTIATION AND SUPPRESSIVE FUNCTION

4.1 ABSTRACT
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of
cells that are defined by their myeloid origin, immature state, and ability to potently
suppress immune response. Murine MDSCs are characterized by the expression of
CD11b and

G-r1 cell markers and can be subdivided into two groups, monocytic and

polymorphonuclear MDSCs based on the expression of Ly6C and Ly6G molecules.
Previously, we found that 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), an Ahr high
affinity binding ligand induces MDSCs and MDSC subset migration from bone marrow
to peritoneal cavity. In the current study, we demonstrate that oral administration of
3,5,4′-trihydroxy-trans-stilbene (Resveratrol, RSV) reduced the number of MDSCs in the
peritoneal cavity and immobilized these cells in the bone marrow. Cell bioenergetic
profile and suppressive function of MDSCs were evaluated in TCDD group with and
without RSV treatment. MDSCs with RSV treatment exhibited low glycolytic proton
efflux rate (PER) which negatively affected their suppressive functions against T-cell
proliferation. Furthermore, we found by flow cytometry strategy that both TCDD and
RSV play a significant role in monocyte and dendritic cell differentiation and Class IIMHC expression.

In summary, our data revealed that RSV can prevent MDSCs

mobilization, differentiation and suppressive function that was induced by TCDD.
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4.2 INTRODUCTION
Myeloid cells have a significant role in the innate immune response via several
functions including the phagocytosis of pathogens (by macrophages), processing and
presentation of antigens (by dendritic cells (DCs), stimulation of an inflammatory
response (by neutrophils), and promotion of wound healing (by platelets) (191).
Monocytes that derive from bone marrow, migrate to tissue and differentiate into
macrophage and DC. Immature myeloid cells that do not have immunosuppressive
activity are present constantly in health individuals (192). However, the accumulation of
undifferentiated myeloid derived suppresser cells (MDSCs) which have high suppressive
activity against T cells is one of the reasons that contribute to development of cancers,
chronic infections, and autoimmune diseases (193-195). MDSCs consist of two large
group of cells: granulocytic or polymorphonuclear MDSCs (PMN-MDSCs) can be
defined as CD11b+Ly6G+Ly6Clow cells with high side scatter and monocytic MDSCs (MMDSCs) that are defined as CD11b+Ly6G–Ly6Chi cells with low side scatter (22). Both
groups have different phenotypes and suppressive functions (196).
Macrophage in the peritoneal cavity (PerC) have been divided according to their
morphology into two distinct subsets: large peritoneal macrophages (LPMs) are defined
as CD11bhiF4/80hi and express low levels of MHC class II (MHCII) and small peritoneal
macrophage which can be defined as CD11binF4/80in and express high levels of MHCII
(197).
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that
cross talks with environmental, dietary, microbial and metabolic signals to control
complex transcriptional programs in a ligand-specific, cell-type-specific and context-
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specific manner (198). AhR has important role in regulation of innate and adaptive
immunity because it is expressed by numerous of immune cells (199). Previous studies
from our lab showed that AhR activation caused thymus atrophy by upregulation of
genes including Fas, LIGHT, and CD30 that enhance negative selection and lead to
thymic atrophy (85), or by regulation of FasL and NF-kappaB in stromal cells, which in
turn plays a critical role in initiating apoptosis in thymic T cells (86). AhR activation also
reversed Th17/Treg differentiation

for Treg favor in colitis animals model (50).

Expression of hypersensitivity to LPS-induced septic shock with increasing mortality
rate in AhR deficient mice is an indicator of the critical role of AhR in immune system
homeostasis (200). There are also studies that showed how Ahr activation can impair the
differentiation of human monocytes to macrophages or dendritic cells (201, 202). Also,
sustained exposure for over 6 days of bone marrow-derived myeloid precursors from
AhR+/+ or AhR-/- mice to subtoxic doses of BaP showed that AhR-induced gene
regulation is crucial for homeostasis of pro- and anti-inflammatory cytokines during
macrophage activation (203).
A broad range of ligands with agonistic and antagonistic properties and with
various affinity binding sites to AhR have been investigated for their role in
immunomodulation. These ligands could be exogenous such as indole-3-carbinol and
resveratrol or toxic environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD), or could be endogenous ligands such as kynurenine and 6 Formylindolo[3,2b]carbazole (5). Interestingly, AhR activation influences many and different aspects of
immunological function, for example, TCDD and FICZ are high affinity AhR ligands,
however TCDD induce anti-inflammatory molecules/cytokines such as FOXP3 and IL-10
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that suppressed experimental autoimmune encephalomyelitis while FICZ induces proinflammatory cytokine IL-17 and increases the severity of experimental autoimmune
encephalomyelitis in mice (89).
From previous work, we found TCDD (10µg/kg) induced rapid and massive
mobilization of MDSCs and MDSCs subsets such as monocytic and polymorphonuclear
MDSCs from bone marrow to peritoneal cavity. In the present study, we observed that
resveratrol ameliorated immunotoxicity effect of TCDD and attenuated the proportion of
MDSCs and MDSCs subset in the peritoneal cavity. Also, we found both AhR agonist
and antagonists had significant influence on monocyte differentiation in the peritoneal
cavity post treatment.
4.3 MATERIALS AND METHODS
Experimental Animals:
Female mice C57BL/6 mice (6-8) weeks old were purchased from Jackson
laboratory, USA. All mice were housed in specific pathogen-free condition at the
AAALAC-accredited University of South Carolina, School of Medicine, Animal
Resource Facility. All experiments performed using mice in this manuscript were
approved by the Institutional Animal Care and Use Committee (IACUC), University of
South Carolina.
Chemicals and reagents:
TCDD was a kind gift from Dr. Steve Safe (Institute of Biosciences &
Technology, Texas A&M Health Sciences Center, College Station, Texas). Resveratrol
(RSV) was from Sigma-Aldrich (St. Louis, MO). Culture medium reagents (RPMI 1640,
Penicillin-Streptomycin, HEPES, L-Glutamine, FBS, and PBS) were purchased from
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Invitrogen Life Technologies (Carlsbad, CA). The following antibodies were used for
surface markers staining were purchased from BioLegend (San Diego, CA-USA): Alexa
Fluor 700-conjugated anti-CD11b, BV510-conjugated-Gr-1, Alexa Fluor 488-conjugated
anti-Ly6C, BV785-conjugated anti-Ly6G, BV421-conjugated anti-MHCII, and BV605 or
PE-conjugated anti-CD11c. Fc Blocker reagent was procured from BD Biosciences (San
Diego, USA). PE Positive Selection Kits were purchased from Stem cells Technologies
(Vancouver, BC, Canada). XFp glycolytic rate assay kit and XFP cell mito stress test kit
were purchased from Agilent Technologies.
Animals treatment and flow cytometry staining
C57BL6 mice (n=5) were given 50 mg/kg orally RSV and the following day, they
were injected with 10 µg/kg TCDD and 90 min later they given a second dose of RSV.
Next day, they sacrificed and peritoneal exudates harvested and stained for flow
cytometry. Flow cytometry analysis was performed using BD FACs Celeste and FlowJo
software from ThermoFisher Scientific.
Flow cytometry to evaluate immune cell phenotypes
Cells were harvested from peritoneal cavity of naïve, RSV, TCDD, and
RSV+TCDD mice and stained with CD11b and Gr-1 to identify MDSCs (CD11b+Gr-1+)
and

LY6C

and

LY6G

to

identify

Monocytic

(CD11b+Ly6G–Ly6Chi)

and

Polymorphonuclear (CD11b+Ly6G+Ly6Clo) MDSCs as described by us previously (103).
According to flow cytometer strategy of gating (204), we stained with CD11b and F4/80
to define monocytes (CD11b+F4/80-), LPM (CD11b+F4/80+), and SPM (CD11binF4/80in).
CD11c and Gr-1 markers used after gating on CD11b to determine Neutrophils (CD11cGr-1+), Dendritic (CD11c+Gr-1-), and nonNCorDC (CD11c-Gr-1-). Also, MHCII

84

expression detected in LPM, SPM, MDSCs, and nonNCorDC. Flow cytometry analysis
was performed using BD FACs Celeste and FlowJo software from ThermoFisher
Scientific.
Purification of MDSCs
MDSCs were purified from

peritoneal exudates of RSV, TCDD, and

RSV+TCDD mice, as described previously (31). In brief, peritoneal exudates were
collected and labeled with PE-conjugated Gr-1 antibody. PE-selection kit from Stem
Cells Technologies was used for selection by following the protocol from company. After
purification, flow cytometry (BD FACScelesta) was used to assess the purity of MDSCs.
Effect of MDSCs from TCDD or RSV+TCDD on T-cell proliferation in vitro.
To examine the suppressive effect of MDSCs on T-cell proliferation, splenocytes
(5x105) from C57BL/6 naïve mice were cultured in the presence of Con-A (2µg/ml)
together with

1:0.5 ratios of MDSCs from TCDD or RSV+TCDD for 24 hrs, as

described (104). [3H]thymidine (1µCi/well) was added to the cell cultures and after 18
hrs, radioactivity was measured using a liquid-scintillation counter (MicroBeta Trilux;
PerkinElmer Life and Analytical Sciences).
Measuring Glycolytic Rate
Proton efflux rate (PER) was measured in 2×105 purified MDSCs from peritoneal
cavity of RSV, TCDD, and RSV+TCDD-treated mice using XF Extracellular Flux
Analyzer (Seahorse Bioscience). MDSCs were plated in XF cell culture plate coated with
15 μg CellTak in phenol red-free Base Medium enriched with 2 mM glutamine, 10 mM
glucose, 1 mM pyruvate, and 5 mM HEPES as initial conditions. Cells monitored under
stressed conditions and in response to 0.5 µM Rotenone plus Antimycin A (Rot/AA) and
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50 mM 2-Deoxy-D-glucose (2-DG). PER quantified by Seahorse Bioscience XFp
Extracellular Flux Analyzer (Agilent Technologies).
4.4 RESULTS
RSV attenuated MDSCs mobilization from bone marrow to peritoneal cavity.
From previous work, we found that TCDD caused massive mobilization of
MDSCs to the peritoneal exudate. While TCDD and RSV both are AhR ligands, TCDD
has high binding affinity towards AhR (205) while RSV binds to AhR with low affinity
(92) Moreover studies from our lab have previously shown that based on the dose of
RSV, it can also act as an antagonist for AhR (205). Thus, in the current study, we
investigated if RSV would reverse the ability of TCDD to induce MDSCs. We observed
that the proportion and absolute numbers of MDSCs in bone marrow of TCDD-treated
mice decreased significantly within 16 hours of exposure while we noted significant
increase in MDSCs in the peritoneal cavity (Fig 4.1A-D). Interestingly, RSV+TCDD
treated groups showed reversal of TCDD effects inasmuch as there were more numbers
of MDSCs in the bone marrow while there was less MDSCs induced in the peritoneal
cavity (Fig 4.1A-D). A similar trend was seen at 24 hours in the peritoneal cavity (Fig
4.1E-F).
RSV impaired glycolytic rate and suppressive function of TCDD-induced MDSCs.
Next, we tested the Proton Efflux Rate (PER) in MDSCs that were induced by
TCDD with or without RSV. Interstitially, we found that RSV impaired PER in MDSCs
cells compared to MDSCs treated with TCDD (Fig 4.2A). Also, all PER parameters
including basal glycolysis, percentage of PER, and compensatory glycolysis were
reduced in RSV+TCDD group when compared to TCDD (Fig 4.2B). When we tested the
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suppressive function of MDSCs, we found that MDSCs from TCDD treated mice were
highly immunosuppressive while MDSCs from RSV+TCDD mice were less
immunosuppressive when compared to TCDD-treated mice (Fig 4.2C). Together, these
data demonstrated that RSV is capable to reducing the migration, and function of TCDDinduced MDSCs.
RSV and TCDD, AhR ligands influence in peritoneal cavity monocytes
differentiation
We also examined if Ahr activation by TCDD influences in the differentiation of
monocytes in murine peritoneal cavity. According to flow cytometer strategy of gating
(204), we found that the proportion of CD11b+ monocytes reduced significantly in TCDD
group when compared to other groups.

Small peritoneal macrophages (SPM)

CD11binF4/80in, were seen in all experimental groups at low levels. However, there was a
significant difference between naïve and RSV and between TCDD and RSV+TCDD
groups. Peritoneal cells from RSV expressed higher percentages of large peritoneal
macrophage (LPM) that were CD11b+F4/80+ when compared to cells in TCDD and
RSV+TCDD (Fig 4.3B,K). MDSCs as well as PMN-MDSCs and M-MDSCs increased
markedly in TCDD group and RSV attenuated this effect (Fig 4.3C,D,L). Dendritic cells
(CD11c+Gr-1-) increased in peritoneal of RSV+TCDD compared to TCDD, and
neutrophils (CD11c-Gr-1+) exhibited high level expression in TCDD, while showing
decreased presence in RSV+TCDD groups. Non-DC or NC CD11b-CD11c- were in high
proportion in naïve mice and decreased dramatically in TCDD while RSV+TCDD
showed an increase when compared to TCDD (Fig 4.3E,M). MHCII was expressed at
higher levels in SPM, while it’s expression in LPM was lower and increased gradually
with TCDD and RSV+TCDD. Like SPM, nonDCorNC expressed high MHCII (Fig
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4.3F,I,M), while in contrast, the expression of MHCII was lacking in MDSCs. However,
MDSCs in RSV treated group exhibited higher levels of MHCII expression (Fig 4.3G,N),
demonstrating a virous effect of Ahr ligand on differentiation of the peritoneal cavity
monocytes.
4.5 DISSUCSION
TCDD and other aryl hydrocarbon receptor (AhR) xenobiotic ligands, such as
polycyclic aromatic hydrocarbons (PAHs), are environmental toxicants generated by the
chemical industry. They are present in air pollution from industrial furnace gas and
burning processes. Many AhR ligands, especially the halogenated have long biological
half-life in body fat which keep increasing with time (206). Resveratrol a polyphenolic
natural compound has been extensively studied for its therapeutic benefits against a wide
array of diseases including cancer, cardiovascular, neurological and inflammatory
diseases (62, 66, 81, 82, 122). In the current study, we investigated other protective role
of RSV against immunotoxicity effect of TCDD. We found that RSV attenuated the
massive mobilization of MDSCs from bone marrow to peritoneal cavity in TCDD
treatment (Fig 4.1). Both TCDD and RSV are AhR agonists and binding to different
residues binding domain (AhRLBD) in AhR. However, some of the residues in AhR
LBD contribute significantly to binding with the ligands (92) that lead to create a kind of
competition between the ligands on binding site. Also, our previous studies have shown
that RSV can both act as an agonist and antagonist based on the dose (207) .
Tumor-infiltrating MDSC (T-MDSC) increase fatty acid uptake and activated
fatty acid oxidation (FAO) that is accompanied by an increase in oxygen consumption
rate (208). Thus, FAO inhibition alone significantly delayed tumor growth in a T-cell-
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dependent manner and enhanced the antitumor effect of adoptive T-cell therapy (26). In
the present study, we observed that RSV impaired protein efflux rate during glycolysis
that was seen at high levels with TCDD treatment (Fig 4.2A-B). Inhibition glycolysis by
RSV potentially had a reduced effect on suppressive function of MDSCs in T-cells
proliferation (Fig 4.2C).
AhR is expressed at high levels in monocytes, macrophage, Th17, ILC3 and DC,
inducible in B cells and NK, and low levels in Th1, Th2, ILC1and2, and granulocytes
(209). Because AhR is expressed highly in monocytes, activation AhR by their agonists
perhaps control monocyte differentiation. A couple studies addressed this question and
found that activation of AhR impeded the differentiation of myeloid cells to macrophage
(202, 203). In the present study, we found that TCDD impaired the proportion of
peritoneal macrophage subset, LPM and SPM. However, LPM with RSV treatment
exhibited higher percentages demonstrating that both ligands have differential effects on
LPM differentiation. Induction of LMP and SMP by RSV can be one of reasons behand
reduced MDSCs population in TCDD with RSV (Fig 4.3B,K). Also, increase of DC
expression with RSV+TCDD may be because DC express highly level of AhR that lead
to increase the proportion of these cells with two ligands. NonDCorNC show a high
proportion in naïve mice when compared to treatments, giving evidence for critical roles
of both TCDD and RSV in monocytes differentiation (Fig 4.3E,M). RSV also caused a
decrease in MDSC subsets, PMN-MDSCs and M-MDSCs when compared to TCDD (Fig
4.3C,L) which correlated with a decrease in MDSC induction as well. SPM expresses
high levels of MHCII, which is not expressed on LPM (204). Similarly, we found SPM
in all experimental groups expressed MHCII, however the expression of MHCII in LPM
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increased with RSV+TCDD, which may explains why RSV treatment reduces the
suppressive activity of MDSCs (Fig 4.3F,I,M). MDSCs normally

lack

MHCII

expression and it can be distinguished from monocytes by this feature (196). We
observed that MHCII expression in MDSCs in TCDD was negligible, however MDSCs
with RSV showed slight increase in MHCII (Fig 4.3G,N) that may have also caused
reversal of suppressive functions (Fig 2).
In summary, the current study demonstrates that RSV can neutralize the
immunotoxicity of TCDD. Specifically, RSV decreased the induction of MDSCs by
TCDD.

Also, RSV reversed the immunosuppressive functions of TCDD -induced

MDSCs against T cell proliferation. Lastly, TCDD also altered the differentiation of
dendritic cells and monocytes and RSV also interfered in this process. Clearly additional
studies are necessary to understand if the effect of TCDD on monocytes and DCs results
from maturation of MDSCs or if this is an independent effect directly on these cells.
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Figure 4.1: Resveratrol (RSV) attenuated MDSCs mobilization from bone marrow
to the peritoneal cavity. Mice were given prior 50 mg/kg orally RSV, next day they
injected with 10 µg/kg TCDD and 90 min later they given a second dose of RSV. Next
day they sacrificed and peritoneal exudates harvested to stain with CD11b Gr-1 to
identify MDSCs and LY6C and LY6G to identify monocytic M-MDSCs and
polymorphonuclear PMN-MDSCs respectively. (A) Representative plots from flowjo
software analysis of flow cytometry data showing MDSCs proportion in BM in 0 hr and
after 16 hrs. (B) Representative pseudocolor plots showing MDSCs proportion in
peritoneal exudate in 0 hr and 16 hrs later. (C) Absolute number of bon marrow-MDSCs
(BM-MDSCs) in 0 hr and after 16 hrs. (D) Absolute number of peritoneal cavity-MDSCs
(PC-MDSCs) in 0 hr and 16 hrs later. (E,F) Percentage and absolute number of MDSCs
in peritoneal cavity in 24 hrs later. Vertical bars represent mean ± SEM. Student’s t test
and one way ANOA *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 4.2: RSV impaired protein efflux rate (PER) and immunosuppressive
function in MDSCs. MDSCs were purified from the peritoneal cavity of RSV, TCDD,
and RSV+TCDD mice as described in material and methods and utilized for PER and
3H-thymidine assays. (A) Proton efflux rate in peritoneal MDSCs in three experimental
groups. (B) Glycolysis parameters quantification including glycolysis, percentage of
PER, and compensatory glycolysis in RSV, TCDD, and RSV+TCDD. (C) Purified
peritoneal MDSCs from TCDD and RSV+TCDD were incubated with spleen cells
activated with ConA at 1:0.5. T cell proliferation was assessed by 3H-thymidine
incorporation assay. in Vertical bars represent mean ± SEM. Student’s t test *p < 0.05;
**p < 0.01; ***p < 0.001.
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Figure 4.3: Flow gating strategy to identify immune cells in the peritoneal cavity.
Based on surface molecules, peritoneal fluid cells in naïve, RSV, TCDD, and
RSV+TCDD stained for. (A) Single cells selection by gating on FSC-H and FSC-A. (B)
Single cells gated on CD11b and F4/80 to identify monocytes CD11b+F4/80-, large
peritoneal macrophage (LPM) can be defined as CD11b+F4/80+ cells with high side
scatter, small peritoneal macrophage (SPM) can be defined as CD11binF4/80in with
intermediate side scatter. (C) MDSCs CD11b+Gr-1+ gated on single cells. (D)
Polymorphonuclear (PMN) and Monocytic (M) MDSCs gated on CD11b. (E) Gr-1 and
CD11c gated on CD11b to identify Neutrophils Gr-1+CD11c-, Dendritic cells CD11c+Gr1- as well as CD11c- Gr-1- NonNCorDC. (F,I) MHCII expression on LPM, SPM, and
NonNCorDC. (G) MHCII expression on MDSCs. (K) Percentage of Monocytes, LPM,
SPM, and MDSCs. (L) Percentage of MDSCs subset population. (M) DC, NC and
NonNCorDC proportion. (N) MHCII expression in LPM, SPM, NonNCorDC and
MDSCs. Vertical bars represent mean ± SEM. One way ANOVA test *p < 0.05;
**p < 0.01; ***p < 0.001.
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CHAPTER 5
SUMMARY AND CONCLUSION
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that
acts as biological sensor by initiating gene expression programs in response to
endogenous and exogenous signals. One of the contaminant exogenous ligands that has
high affinity binding to AhR with immunotoxic and carcinogenic properties is TCDD
(2,3,7,8-Tetrachlorodibenzo-p-dioxin). The data presented in this dissertation showed
that TCDD caused significant immunomodulation and alterations in gut microbiota. On
the other hand, resveratrol, a natural polyphenolic compound with known agonistic and
antagonistic activity attenuated immunomodulatory effects of TCDD.
TCDD induced immunomodulation included massive mobilization of MDSCs
from bone marrow to peritoneal cavity that was associated with increases in several
chemokines and their receptors. TCDD-induced MDSCs were highly immunosuppressive
as demonstrated using in vitro and adoptive transfer experiments which correlated with
increase in bioenergetic profile of these cells. TCDD also caused epigenetic modification
in MDSCs that was accompanied with down-regulation in the expression of miR-150-5p
and miR-543-3p which led to increase in the expression of target genes including IL-10,
PIM1, ARG2, STAT3, and CCL11 and chemokines receptors CCR3, CCR5, and
CXCR2. Upregulation of these anti-inflammatory genes, chemokines, and their receptors
played a major role in the migration, expansion and function of MDSCs.

94

The influence of TCDD was not limited only to the immune system, TCDD also
caused shift in the resident gut microbiome, particularly through increasing Lactobacillus
and decreasing Sutterella abundances. FMT experiments confirmed that TCDD-mediated
changes in the gut microbiome altered the immune system, specifically by increasing the
MDSCs in a CXCR2-dependent manner, which resulted in decreased cysteine levels.
Data presented in the current work also provide evidence for neutralizing the
immunotoxicity of TCDD. Resveratrol, a natural compound, was found to reduce
significantly the massive MDSC mobilization to the peritoneal cavity and reversed their
suppressive function.
Together, these studies demonstrate for the first time how AhR activation by
ligands can serve as a double-edged sword on one hand inducing MDSCs that may be
beneficial to treat inflammatory and autoimmune diseases while on the other hand
promoting cancer. This may explain how some dietary AhR ligands may help suppress
inflammation in the colon and systemically, while some environmental toxicants such as
TCDD and methyl cholanthrene may induce cancer. Our studies form the basis for
further investigations into such mechanisms which may help develop novel therapies to
treat inflammatory and autoimmune diseases as well as prevent cancers induced by
environmental contaminants.
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